<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006296.pub2" GROUP_ID="ENDOC" ID="936905021509504009" MERGED_FROM="" MODIFIED="2009-05-12 16:53:03 +0200" MODIFIED_BY="Bernd Richter" REVIEW_NO="R_I_09_1" REVMAN_SUB_VERSION="5.0.20" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="3.0">
<COVER_SHEET MODIFIED="2009-05-12 16:53:03 +0200" MODIFIED_BY="Bernd Richter">
<TITLE>Low glycaemic index, or low glycaemic load, diets for diabetes mellitus</TITLE>
<CONTACT MODIFIED="2009-05-12 16:53:03 +0200" MODIFIED_BY="Bernd Richter"><PERSON ID="14749" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Diana</FIRST_NAME><LAST_NAME>Thomas</LAST_NAME><POSITION>Scientific Director</POSITION><EMAIL_1>dianat@chw.edu.au</EMAIL_1><EMAIL_2>drdthomas@hotmail.com</EMAIL_2><ADDRESS><DEPARTMENT>Centre for Evidence Based Paediatrics Gastroenterology and Nutrition (CEBPGAN)</DEPARTMENT><ORGANISATION>The Children's Hospital at Westmead, The University of Sydney</ORGANISATION><ADDRESS_1>Locked Bag 4001</ADDRESS_1><CITY>Westmead</CITY><ZIP>NSW 2145</ZIP><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 2 98451203</PHONE_1><FAX_1>+61 2 98453082</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2009-05-12 16:53:03 +0200" MODIFIED_BY="Bernd Richter"><PERSON ID="14749" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Diana</FIRST_NAME><LAST_NAME>Thomas</LAST_NAME><POSITION>Scientific Director</POSITION><EMAIL_1>dianat@chw.edu.au</EMAIL_1><EMAIL_2>drdthomas@hotmail.com</EMAIL_2><ADDRESS><DEPARTMENT>Centre for Evidence Based Paediatrics Gastroenterology and Nutrition (CEBPGAN)</DEPARTMENT><ORGANISATION>The Children's Hospital at Westmead, The University of Sydney</ORGANISATION><ADDRESS_1>Locked Bag 4001</ADDRESS_1><CITY>Westmead</CITY><ZIP>NSW 2145</ZIP><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 2 98451203</PHONE_1><FAX_1>+61 2 98453082</FAX_1></ADDRESS></PERSON><PERSON ID="16099" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Elizabeth</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Elliott</LAST_NAME><POSITION>Consultant Paediatrician</POSITION><EMAIL_1>elizabe2@chw.edu.au</EMAIL_1><ADDRESS><DEPARTMENT>Department of Paediatrics and Child Health, Director of Centre for Evidence Based Paediatric Gastroenterology and Nutrition (CEBPGAN)</DEPARTMENT><ORGANISATION>The Children's Hospital at Westmead; The University of Sydney</ORGANISATION><ADDRESS_1>Locked Bag 4001</ADDRESS_1><CITY>Westmead</CITY><ZIP>2145</ZIP><REGION>NSW</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 2 9845 3448</PHONE_1><FAX_1>+61 2 9845 3389</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2009-05-04 12:35:49 +0200" MODIFIED_BY="Gudrun Paletta">
<UP_TO_DATE>
<DATE DAY="30" MONTH="6" YEAR="2008"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="30" MONTH="6" YEAR="2008"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="12" MONTH="11" YEAR="2010"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2006"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2009"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2009"/>
</DATES>
<WHATS_NEW MODIFIED="2009-05-12 16:50:58 +0200" MODIFIED_BY="Bernd Richter">
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2009-05-12 16:50:58 +0200" MODIFIED_BY="Bernd Richter">
<DATE DAY="12" MONTH="5" YEAR="2009"/>
<DESCRIPTION>
<P>Clarification about the description of the intervention</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-10-08 14:01:17 +0200" MODIFIED_BY="[Empty name]"/>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>The Children's Hospital at Westmead, NSW</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>University of Sydney</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Elizabeth Elliott is supported by a National Health and Medical Research Fellowship (457084)</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-11-21 11:06:31 +0100" MODIFIED_BY="Bernd Richter">
<SUMMARY MODIFIED="2008-11-12 11:29:34 +0100" MODIFIED_BY="Bernd Richter">
<TITLE MODIFIED="2008-10-08 14:02:44 +0200" MODIFIED_BY="[Empty name]">Low glycaemic index, or low glycaemic load, diets for diabetes mellitus</TITLE>
<SUMMARY_BODY MODIFIED="2008-11-12 11:29:34 +0100" MODIFIED_BY="Bernd Richter">
<P>Nutritional factors affect blood glucose levels, however there is currently no universal approach to the optimal dietary strategy for diabetes. Different carbohydrate foods have different effects on blood glucose and can be ranked by the overall effect on the blood glucose levels using the so-called glycaemic index. By contributing a gradual supply of glucose to the bloodstream and hence stimulating lower insulin release, low glycaemic index foods, such as lentils, beans and oats, may contribute to improved glycaemic control, compared to high glycaemic index foods, such as white bread. The so-called glycaemic load represents the overall glycaemic effect of the diet and is calculated by multiplying the glycaemic index by the grammes of carbohydrates.</P>
<P>We identified eleven relevant randomised controlled trials, lasting 1 to 12 months, involving 402 participants. Metabolic control (measured by glycated haemoglobin A1c (HbA1c), a long-term measure of blood glucose levels) decreased by 0.5% HbA1c with low glycaemic index diet, which is both statistically and clinically significant. Hypoglycaemic episodes significantly decreased with low glycaemic index diet compared to high glycaemic index diet. No study reported on mortality, morbidity or costs.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-11-12 11:28:02 +0100" MODIFIED_BY="Bernd Richter">
<ABS_BACKGROUND MODIFIED="2008-11-06 15:01:48 +0100" MODIFIED_BY="Bernd Richter">
<P>The aim of diabetes management is to normalise blood glucose levels, since improved blood glucose control is associated with reduction in development, and progression, of complications. Nutritional factors affect blood glucose levels, however there is currently no universal approach to the optimal dietary treatment for diabetes. There is controversy about how useful the glycaemic index (GI) is in diabetic meal planning. Improved glycaemic control through diet could minimise medications, lessen risk of diabetic complications, improve quality of life and increase life expectancy.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2008-11-06 15:02:28 +0100" MODIFIED_BY="Bernd Richter">
<P>To assess the effects of low glycaemic index, or low glycaemic load, diets on glycaemic control in people with diabetes.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2008-10-08 14:03:47 +0200" MODIFIED_BY="[Empty name]">
<P>We performed electronic searches of <I>The Cochrane Library</I>, MEDLINE, EMBASE and CINAHL with no language restriction.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>We assessed randomised controlled trials of four weeks or longer that compared a low glycaemic index, or low glycaemic load, diet with a higher glycaemic index, or load, or other diet for people with either type 1 or 2 diabetes mellitus, whose diabetes was not already optimally controlled.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Two reviewers independently extracted data on study population, intervention and outcomes for each included study, using standardised data extraction forms.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2008-11-12 11:28:02 +0100" MODIFIED_BY="Bernd Richter">
<P>Eleven relevant randomised controlled trials involving 402 participants were identified. There was a significant decrease in the glycated haemoglobin A1c (HbA1c) parallel group of trials, the weighted mean difference (WMD) was  -0.5% with a 95% confidence interval (CI) of - 0.9 to -0.1, P = 0.02; and in the cross-over group of trials the WMD was -0.5% with a 95% CI of -1.0 to -0.1, P = 0.03. Episodes of hypoglycaemia were significantly fewer with low compared to high GI diet in one trial (difference of -0.8 episodes per patient per month, P &lt; 0.01), and proportion of participants reporting more than 15 hyperglycaemic episodes per month was lower for low-GI diet compared to measured carbohydrate exchange diet in another study (35% versus 66%, P = 0.006). No study reported on mortality, morbidity or costs.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2008-11-12 11:23:27 +0100" MODIFIED_BY="Bernd Richter">
<P>A low-GI diet can improve glycaemic control in diabetes without compromising hypoglycaemic events.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-11-21 11:06:31 +0100" MODIFIED_BY="Bernd Richter">
<BACKGROUND MODIFIED="2008-11-06 15:30:45 +0100" MODIFIED_BY="Bernd Richter">
<CONDITION MODIFIED="2008-11-06 15:23:45 +0100" MODIFIED_BY="Bernd Richter">
<P>Diabetes mellitus is a metabolic disorder resulting from a defect in insulin secretion, insulin action, or both. A consequence of this is chronic hyperglycaemia (that is elevated levels of plasma glucose) with disturbances of carbohydrate, fat and protein metabolism. Long-term complications of poorly controlled diabetes mellitus include retinopathy, nephropathy and neuropathy, and increased risk of cardiovascular disease. The prevalence of type 2 diabetes is increasing and is being diagnosed at increasingly younger ages (<LINK REF="REF-Silink-2002" TYPE="REFERENCE">Silink 2002</LINK>). For a detailed overview of diabetes mellitus, please see under 'Additional information' in the Metabolic and Endocrine Disorders Group section in <I>The Cochrane Library</I> (see 'About', 'Cochrane Review Groups (CRGs)'). For an explanation of methodological terms, see the main glossary in <I>The Cochrane Library</I>.</P>
</CONDITION>
<INTERVENTION MODIFIED="2008-11-06 15:27:06 +0100" MODIFIED_BY="Bernd Richter">
<P>The aim of diabetes management is to normalise blood glucose levels, since improved blood glucose control is associated with a reduction in the development of, and progression of, complications (<LINK REF="REF-Stratton-2000" TYPE="REFERENCE">Stratton 2000</LINK>). Nutritional factors affect blood glucose levels, however there is currently no universal approach to the optimal dietary strategy for diabetes (<LINK REF="REF-ADA-2008" TYPE="REFERENCE">ADA 2008</LINK>). Improvement in glycaemic control achieved through dietary interventions would lessen the risk of diabetic complications, improve quality of life for people with diabetes, increase their life expectancy, and minimise, or even avoid, the necessity for expensive medications and diabetic health care. Different carbohydrate foods have different effects on blood glucose and can be ranked by the overall effect on the blood glucose levels using the glycaemic index (<LINK REF="REF-Jenkins-1981" TYPE="REFERENCE">Jenkins 1981</LINK>). By contributing a gradual supply of glucose to the bloodstream and hence stimulating lower insulin release, low glycaemic index foods, such as lentils, beans and oats, may contribute to improved glycaemic control, compared to high glycaemic index foods, such as white bread (<LINK REF="REF-Jenkins-1981" TYPE="REFERENCE">Jenkins 1981</LINK>). Low glycaemic index diets may increase insulin sensitivity by minimising fluctuations in blood glucose levels and reducing the secretion of insulin over the day (<LINK REF="REF-Crapo-1977" TYPE="REFERENCE">Crapo 1977</LINK>). The glycaemic load represents the overall glycaemic effect of the diet and is calculated by multiplying the glycaemic index by the grammes of carbohydrates (<LINK REF="REF-Salmeron-1997" TYPE="REFERENCE">Salmeron 1997</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2008-11-06 15:30:45 +0100" MODIFIED_BY="Bernd Richter">
<P>There is controversy over how useful the glycaemic index or glycaemic load is in meal planning for people with diabetes. The authors of a recent Cochrane systematic review concluded that there were no high-quality data on the efficacy of diet alone for the treatment of type 2 diabetes (<LINK REF="REF-Nield-2008" TYPE="REFERENCE">Nield 2008</LINK>), but low glycaemic index diets were not one of the diets considered in that review. However, in another review, it was concluded that low glycaemic index diets exert a small, but clinically useful effect on medium-term glycaemic control in diabetes (<LINK REF="REF-Brand_x002d_Miller-2003" TYPE="REFERENCE">Brand-Miller 2003</LINK>).</P>
<P>The American Diabetes Association recommends that "with regard to the glycaemic effects of carbohydrates, the total amount of carbohydrate in meals or snacks is more important than the source or type" (<LINK REF="REF-ADA--2004" TYPE="REFERENCE">ADA 2004</LINK>). This recommendation was based on five studies (<LINK REF="REF-Franz-2004" TYPE="REFERENCE">Franz 2004</LINK>) in all of which glycated haemoglobin levels did not change. However, all these studies had interventions of six weeks or less and percentage glycated haemoglobin reflects glycaemic control over two to three months (<LINK REF="REF-ADA--2004" TYPE="REFERENCE">ADA 2004</LINK>). Short trials, however, may show differences in the degree of glycation of serum proteins (mostly albumin), measured by fructosamine or glycated serum albumin (GSA) assays, since these tests reflect glycaemic control during the preceding one to four weeks (<LINK REF="REF-ADA--2004" TYPE="REFERENCE">ADA 2004</LINK>; <LINK REF="REF-Goldstein--1995" TYPE="REFERENCE">Goldstein 1995</LINK>; <LINK REF="REF-Winocour-1988" TYPE="REFERENCE">Winocour 1988</LINK>). Four of the five studies (<LINK REF="REF-Franz-2004" TYPE="REFERENCE">Franz 2004</LINK>) reported either fructosamine or GSA results, which decreased after the low glycaemic index diet, indicating a positive effect on glycaemic control.</P>
<P>The most recent position statement from the American Diabetes Association (ADA) maintains that glycaemic control is best attained through monitoring total carbohydrate via carbohydrate counting, exchange or by experienced-based estimation (<LINK REF="REF-ADA-2008" TYPE="REFERENCE">ADA 2008</LINK>). This ADA position statement considers that use of glycaemic index or load may provide possibly only a modest secondary benefit above consideration of total carbohydrate alone (<LINK REF="REF-ADA-2008" TYPE="REFERENCE">ADA 2008</LINK>), even though questions on the glycaemic index were considered in an ADA statement issued in 2004 (<LINK REF="REF-Sheard-2004" TYPE="REFERENCE">Sheard 2004</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2008-10-08 14:04:36 +0200" MODIFIED_BY="[Empty name]">
<P>Our Cochrane systematic review may clarify issues surrounding the role of low glycaemic index, or low glycaemic load, diets in the management of diabetes mellitus. Our review will include all relevant studies with diet interventions lasting four weeks or longer. If alterations in the glycaemic index or glycaemic load of the diet can alone improve glycaemic control in diabetes, the use of low glycaemic index, or low glycaemic load, diets could have significant health and cost benefits for people with diabetes and the community as a whole.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES>
<P>To assess the effects of low glycaemic index, or low glycaemic load, diets on glycaemic control in people with diabetes.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-11-12 11:37:07 +0100" MODIFIED_BY="Bernd Richter">
<SELECTION_CRITERIA MODIFIED="2008-11-12 11:25:44 +0100" MODIFIED_BY="Bernd Richter">
<CRIT_STUDIES MODIFIED="2008-11-06 14:42:24 +0100" MODIFIED_BY="Bernd Richter">
<SUBSECTION>
<HEADING LEVEL="4">Inclusion criteria</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Trial Design</HEADING>
<P>We considered all randomised controlled trials that compared a low glycaemic index, or low glycaemic load, diet with a higher glycaemic index diet for people with diabetes.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Trial Duration</HEADING>
<P>We included trials with dietary interventions lasting four weeks or longer. Efficacy was assessed as short term (if follow-up was less than six months), intermediate (six months to less than 12 months) and long-term (12 months and over).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Exclusion criteria</HEADING>
<P>We excluded studies in which the intervention was only a generalised recommendation to increase the proportion of low glycaemic index foods in the diet, or to reduce the glycaemic load, without provision of explicit detail; studies in which the intervention was either not directly supervised or well-documented, for example, through the use of food diaries or the provision of food; studies in which there was a co-intervention in the experimental group that was not also applied to the control group.</P>
</SUBSECTION>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Participants were males and females of any age who were classified as having diabetes mellitus using validated and specified criteria. To be consistent with changes in classification and diagnostic criteria of diabetes mellitus through the years, the diagnosis should have been established using the standard criteria valid at the time of the beginning of the trial. Ideally, diagnostic criteria should have been described. If necessary, the authors' definition of type 2 diabetes mellitus was used.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>We included studies that compared a low glycaemic index, or low glycaemic load, diet with a higher glycaemic index diet or other diets.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-11-12 11:25:44 +0100" MODIFIED_BY="Bernd Richter">
<P>Glycated haemoglobin is the best measure of long-term glycaemic control, since it represents the average blood glucose levels over several months (<LINK REF="REF-ADA--2004" TYPE="REFERENCE">ADA 2004</LINK>; <LINK REF="REF-UKPDS-38-1998" TYPE="REFERENCE">UKPDS 38 1998</LINK>; <LINK REF="REF-UKPDS33-1998" TYPE="REFERENCE">UKPDS33 1998</LINK>). Hence, for the review, glycated haemoglobin was defined as the main outcome measure of glycaemic control for studies where the intervention lasted over six weeks. Fructosamine or glycated serum albumin (GSA) levels were used, when provided, as the measure of glycaemic control for studies where the intervention lasted six weeks or less, since in these cases, fructosamine or GSA levels are more reliable indicators of glycaemic control than the degree of glycation of haemoglobin (<LINK REF="REF-ADA--2004" TYPE="REFERENCE">ADA 2004</LINK>; <LINK REF="REF-Winocour-1988" TYPE="REFERENCE">Winocour 1988</LINK>). The turnover of human serum albumin is much shorter (half-life of 14 to 20 days) than that of haemoglobin (erythrocyte life span 120 days), so the degree of glycation of serum proteins (mostly albumin), indicated by fructosamine or GSA, shows the level of glycaemia better over shorter time periods than does glycation of haemoglobin (<LINK REF="REF-ADA--2004" TYPE="REFERENCE">ADA 2004</LINK>). "Measurements of total glycated serum protein and GSA correlate well with one another and with measurements of glycated haemoglobin" (<LINK REF="REF-ADA--2004" TYPE="REFERENCE">ADA 2004</LINK>; <LINK REF="REF-Goldstein--1995" TYPE="REFERENCE">Goldstein 1995</LINK>).<BR/>
<BR/>
</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2008-11-12 11:25:44 +0100" MODIFIED_BY="Bernd Richter">
<UL>
<LI>glycaemic control as measured by glycated haemoglobin, fructosamine, glycated serum albumin or other test measuring glycated proteins;</LI>
<LI>adverse effects.</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2008-11-06 15:44:14 +0100" MODIFIED_BY="Bernd Richter">
<UL>
<LI>insulin action (fasting plasma insulin, insulin sensitivity, insulin area under the curve, total insulin released per day, insulin-to-glucose ratio);</LI>
<LI>morbidity (for example diabetes and cardiovascular related morbidity, like angina pectoris, myocardial infarction, stroke, peripheral vascular disease, neuropathy, retinopathy, nephropathy, erectile dysfunction, amputation);</LI>
<LI>quality of life (using a validated instrument);</LI>
<LI>costs;</LI>
<LI>mortality.</LI>
</UL>
<SUBSECTION>
<HEADING LEVEL="5">Timing of outcome assessment (length of intervention)</HEADING>
<P>Studies were classified as short term (less than six months), medium term (six to less than twelve months), or long-term (12 months and over), according to the timing of the final outcome assessments after the intervention.</P>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-11-06 15:45:07 +0100" MODIFIED_BY="Bernd Richter">
<ELECTRONIC_SEARCHES MODIFIED="2008-11-06 15:45:07 +0100" MODIFIED_BY="Bernd Richter">
<P>We searched the following sources for the identification of trials:</P>
<UL>
<LI>
<I>The Cochrane Library</I> (Issue 2, 2008);</LI>
<LI>MEDLINE (up June 2008);</LI>
<LI>EMBASE (up to June 2008);</LI>
<LI>CINAHL (up to June 2008).</LI>
</UL>
<P>The included search strategy (see detailed search strategy under <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>) was used for MEDLINE. This was slightly modified for searches of EMBASE, <I>The Cochrane Library</I> and CINAHL. We placed no language restrictions on either the search or the included trials.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2008-11-06 12:32:09 +0100" MODIFIED_BY="Bernd Richter">
<P>We hand searched the reference lists of review articles and included studies for other potentially eligible studies.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-11-12 11:37:07 +0100" MODIFIED_BY="Bernd Richter">
<STUDY_SELECTION MODIFIED="2008-11-06 12:59:52 +0100" MODIFIED_BY="Bernd Richter">
<P>Two reviewers independently reviewed the titles, abstract sections and keywords of every record retrieved from the literature searches to identify potentially eligible studies. Articles that clearly do not meet the inclusion criteria were rejected at this initial review. We obtained the full text of the remaining articles for further examination. We assessed each study for eligibility for inclusion against the defined selection criteria and eliminated any trial that did not fulfil this criteria, for example was not a randomised controlled trial, did not involve people who had diabetes, had no comparator, included a co-intervention, or in which the trial period was less than four weeks. The decision to eliminate a trial was based on agreement by both reviewers. We had planned to calculate inter-rater agreement for study selection using Cohen's kappa statistic (<LINK REF="REF-Cohen-1960" TYPE="REFERENCE">Cohen 1960</LINK>; <LINK REF="REF-Fleiss-1981" TYPE="REFERENCE">Fleiss 1981</LINK>), and resolve any differences through discussion. However, the authors identified the same abstracts for further investigation and later for inclusion, so this was not performed. An adapted QUOROM (quality of reporting of meta-analyses) flow-chart of study selection is attached (<LINK REF="REF-Moher-1999" TYPE="REFERENCE">Moher 1999</LINK>) (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2008-10-08 14:23:37 +0200" MODIFIED_BY="[Empty name]">
<P>Two reviewers independently extracted the data on the study population, intervention and outcomes for each included study, using a standardised data extraction form.<BR/>We extracted the following data:<BR/>
</P>
<UL>
<LI>general information: published or unpublished, title, authors, study setting, source, contact address, country, language, year of publication, duplicate publication, funding source;</LI>
<LI>trial characteristics: design, randomisation (and method), allocation concealment (and method), blinding of outcome assessors, withdrawals, losses to follow-up.</LI>
<LI>intervention and comparator; duration;</LI>
<LI>participants: Inclusion criteria, exclusion criteria, number in intervention and comparison groups, sex, age, health status, medication status, type of diabetes, diagnostic criteria, similarity of groups at baseline;</LI>
<LI>outcomes: outcomes specified in the methods, other outcomes assessed in the study;</LI>
<LI>results: For continuous variables, we extracted the number of participants, and the baseline and post-intervention means with standard deviations (SD) or standard error of the mean (SEM) or 95% confidence interval (95% CI) for the intervention and control groups. We transformed SEM or 95% CI into SD, if appropriate. Dichotomous outcomes were also recorded.</LI>
</UL>
<P>Any variations in data extraction were resolved by consensus, referring back to the original data.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2008-11-06 15:49:10 +0100" MODIFIED_BY="Bernd Richter">
<P>Two reviewers independently assessed the methodological quality of each included trial, based on quality criteria specified by Schulz and Jadad (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>; <LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>):<BR/>(1) Minimisation of selection bias - a) was the randomisation procedure adequate? b) was the allocation concealment adequate?<BR/>(2) Minimisation of attrition bias - a) were withdrawals and dropouts completely described? b) was the analysis by intention-to treat?<BR/>(3) Minimisation of detection bias - were the outcome assessors blind to the intervention? Blinding of either the participant or the administrator of the intervention is generally not possible in dietary intervention studies, and it is often not feasible to have an assessor who has had no part in the trial, hence blinding was not assessed as a quality criterion. However, blinding of outcome assessors was recorded.</P>
<P>As there were insufficient trials, sensitivity analyses on the quality of the included trials (A - low risk of bias: all quality criteria met; B - moderate risk of bias: one or more of the quality criteria only partially met; C - high risk of bias: one or more quality criteria not met) were not performed (<I>Cochrane Handbook for Systematic Reviews of Interventions</I>) (<LINK REF="REF-Higgins-2005" TYPE="REFERENCE">Higgins 2005</LINK>).</P>
<P>We had planned to calculate the level of inter-rater agreement on quality assessment using the kappa statistic (<LINK REF="REF-Cohen-1960" TYPE="REFERENCE">Cohen 1960</LINK>; <LINK REF="REF-Fleiss-1981" TYPE="REFERENCE">Fleiss 1981</LINK>), however, as there was no variation, this was not performed.</P>
</QUALITY_ASSESSMENT>
<HETEROGENEITY_ASSESSMENT MODIFIED="2008-11-12 11:37:07 +0100" MODIFIED_BY="Bernd Richter">
<P>We tested for heterogeneity between trial results using the standard &#967;<SUP>2</SUP> test to examine whether any variation in study results could be due to the variation expected by chance alone, with significance set at &#945; = 0.1. Quantification of the effect of heterogeneity was assessed by means of I<SUP>2</SUP>, ranging from 0% to 100% including its 95% confidence interval (<LINK REF="REF-Higgins-2002" TYPE="REFERENCE">Higgins 2002</LINK>). I<SUP>2</SUP> demonstrates the percentage of total variation across studies due to heterogeneity and was used to judge the consistency of evidence. I<SUP>2</SUP> values of 50% and more indicate a substantial level of heterogeneity (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). If heterogeneity had been found, we planned to explore it using subgroup and sensitivity analyses.</P>
<P>Where summarising the results seemed appropriate (sufficiently similar studies of similar quality), we used a random-effects model which assumes the effect size varies across studies. We used intention-to-treat analysis where possible.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2008-11-06 12:59:51 +0100" MODIFIED_BY="Bernd Richter">
<P>Publication bias was explored through assessment of funnel plot asymmetry (<LINK REF="REF-Cooper-1994" TYPE="REFERENCE">Cooper 1994</LINK>; <LINK REF="REF-Tang-2000" TYPE="REFERENCE">Tang 2000</LINK>).</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2008-11-06 15:49:32 +0100" MODIFIED_BY="Bernd Richter">
<P>All data were initially analysed with a fixed effect model. We summarized the data statistically, including meta-analysis of trial results where appropriate, that is if the data were available and results were sufficiently homogeneous and of sufficient quality. For dichotomous outcomes, we planned to express the effect size in terms of relative risk with 95% confidence interval (CI), but no dichotomous outcomes were included in this review.</P>
<P>For continuous outcomes, we calculated weighted mean differences. We extracted the baseline and post-intervention means with standard deviations (SD) (or standard error of the mean (SEM) or 95% confidence interval (CI)) for the intervention and control groups, transforming any SEM or 95% CI into SD where appropriate. For absolute changes in outcome between baseline and post-intervention for the control and intervention groups, mean difference was calculated, if required, by subtracting the control absolute change from the intervention absolute change. The estimate of variance for each of these changes equals Vpre + Vpost - 2r(SEpre x SEpost), where Vpre and SEpre are the variance and standard error of the mean baseline value; Vpost and SEpost are the variance and standard error of the mean post-intervention value; and r is the correlation between baseline and post-intervention values. The variance of the total change is then the sum of the variance of the change in the intervention group and the variance of the change in the control group. If the value of r was not given, we assumed that r equalled 0.5.</P>
<P>When post-intervention measures of dispersion were not given (for example if the results were presented as percentage change from baseline), the baseline measures of dispersion were also used as the post-intervention values. This is a conservative approach, since variation at baseline should be larger than that at post-intervention, but this approach was only taken when pre- and post- measures of dispersion for the same outcome were similar to each other in other trials. If the results were given on different scales, we used standardised mean differences. When data were only presented graphically, an estimate of the mean and SD was obtained from the graph.</P>
<P>Drop-outs, losses to follow-up and withdrawn study participants were investigated. Where there were two papers reporting on the same study, we maximised the yield of information by simultaneous evaluation of all available data, with the original publication given priority.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2008-11-06 14:43:15 +0100" MODIFIED_BY="Bernd Richter">
<P>Subgroup analysis was planned where a primary outcome parameter was statistically significantly different between dietary groups. The following subgroup analyses were planned:</P>
<UL>
<LI>age, less than or equal to 18 years, 19 to 40 years, 41 to 65 years, more than 65 years;</LI>
<LI>duration of trial intervention: short term (less than or equal to three months), medium term (three to six months), long term (more than six months);</LI>
<LI>difference in the glycaemic index, or load, between the intervention and comparator diets; diabetes diagnosis (type 1 or type 2);</LI>
<LI>duration of diabetes; follow-up timing: less than or equal to six months, 6 to 12 months, more than 12 months.</LI>
</UL>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2008-10-08 14:22:53 +0200" MODIFIED_BY="[Empty name]">
<P>We had planned to perform sensitivity analyses to explore the influence of the following factors on effect size, by repeating the analysis:<BR/>
</P>
<UL>
<LI>excluding unpublished studies;</LI>
<LI>taking study quality, as specified above, into account;</LI>
<LI>excluding any long or large studies to determine their influence on the results;</LI>
<LI>excluding studies using the following filters: diagnostic criteria, language of publication, source of funding (industry versus other), country.</LI>
</UL>
<P>However, there were insufficient studies to perform these analyses.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-11-21 11:06:31 +0100" MODIFIED_BY="Bernd Richter">
<STUDY_DESCRIPTION MODIFIED="2008-11-12 11:35:05 +0100" MODIFIED_BY="Bernd Richter">
<SEARCH_RESULTS MODIFIED="2008-11-06 15:56:08 +0100" MODIFIED_BY="Bernd Richter">
<P>From the initial search, 2899 records were identified. From the abstracts of these, we identified 32 papers for examination of the full text. The other papers were excluded on the basis of their abstract because they did not fit the criteria for the review. Main reasons for exclusion were: papers were reviews, not relevant, duplicates, some or all of the participants did not have diagnosed diabetes, study had no control group or no randomisation, studies did not compare similar groups, there was a co-intervention or the intervention was less than four weeks.<BR/>Eleven studies met the inclusion criteria (<LINK REF="STD-Brand-1991" TYPE="STUDY">Brand 1991</LINK>; <LINK REF="STD-Collier-1988" TYPE="STUDY">Collier 1988</LINK>; <LINK REF="STD-Fontvieille-1992" TYPE="STUDY">Fontvieille 1992</LINK>; <LINK REF="STD-Frost-1994" TYPE="STUDY">Frost 1994</LINK>; <LINK REF="STD-Giacco-2000" TYPE="STUDY">Giacco 2000</LINK>; <LINK REF="STD-Gilbertson-2001" TYPE="STUDY">Gilbertson 2001</LINK>; <LINK REF="STD-Jimenez_x002d_Cruz-2003" TYPE="STUDY">Jimenez-Cruz 2003</LINK>; <LINK REF="STD-Komindr-2001" TYPE="STUDY">Komindr 2001</LINK>; <LINK REF="STD-Luscombe-1999" TYPE="STUDY">Luscombe 1999</LINK>; <LINK REF="STD-Rizkalla-2004" TYPE="STUDY">Rizkalla 2004</LINK>; <LINK REF="STD-Wolever-1992" TYPE="STUDY">Wolever 1992</LINK>). Six reported percentage glycated haemoglobin (<LINK REF="STD-Brand-1991" TYPE="STUDY">Brand 1991</LINK>; <LINK REF="STD-Giacco-2000" TYPE="STUDY">Giacco 2000</LINK>; <LINK REF="STD-Gilbertson-2001" TYPE="STUDY">Gilbertson 2001</LINK>; <LINK REF="STD-Komindr-2001" TYPE="STUDY">Komindr 2001</LINK>; <LINK REF="STD-Jimenez_x002d_Cruz-2003" TYPE="STUDY">Jimenez-Cruz 2003</LINK>; <LINK REF="STD-Rizkalla-2004" TYPE="STUDY">Rizkalla 2004</LINK>), four reported fructosamine (<LINK REF="STD-Fontvieille-1992" TYPE="STUDY">Fontvieille 1992</LINK>; <LINK REF="STD-Frost-1994" TYPE="STUDY">Frost 1994</LINK>; <LINK REF="STD-Luscombe-1999" TYPE="STUDY">Luscombe 1999</LINK>; <LINK REF="STD-Wolever-1992" TYPE="STUDY">Wolever 1992</LINK>) and one reported glycosylated albumin (<LINK REF="STD-Collier-1988" TYPE="STUDY">Collier 1988</LINK>). One study reported both percentage glycated haemoglobin and fructosamine, but as the intervention was less than six weeks, only the fructosamine results were included (<LINK REF="STD-Fontvieille-1992" TYPE="STUDY">Fontvieille 1992</LINK>). For an adapted QUOROM (quality of reporting of meta-analyses) flow-chart of study selection see <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="4">Missing data</HEADING>
<P>No authors were successfully contacted for further information or clarification.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Assessment of inter-rater agreement</HEADING>
<P>Both authors reviewed the studies, and were in agreement on those to be fully assessed. From these, studies eligible for inclusion in the review were identified. Both authors agreed on the final papers chosen for assessment and on the quality assessment of the studies.</P>
</SUBSECTION>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2008-11-12 11:35:05 +0100" MODIFIED_BY="Bernd Richter">
<P>Details of the characteristics of the included studies are given in the table <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>. The following gives a brief overview:</P>
<SUBSECTION>
<HEADING LEVEL="4">Study types</HEADING>
<P>All eleven studies identified for the review were randomised controlled trials (<LINK REF="STD-Brand-1991" TYPE="STUDY">Brand 1991</LINK>; <LINK REF="STD-Collier-1988" TYPE="STUDY">Collier 1988</LINK>; <LINK REF="STD-Fontvieille-1992" TYPE="STUDY">Fontvieille 1992</LINK>; <LINK REF="STD-Frost-1994" TYPE="STUDY">Frost 1994</LINK>; <LINK REF="STD-Giacco-2000" TYPE="STUDY">Giacco 2000</LINK>; <LINK REF="STD-Gilbertson-2001" TYPE="STUDY">Gilbertson 2001</LINK>; <LINK REF="STD-Jimenez_x002d_Cruz-2003" TYPE="STUDY">Jimenez-Cruz 2003</LINK>; <LINK REF="STD-Luscombe-1999" TYPE="STUDY">Luscombe 1999</LINK>; <LINK REF="STD-Komindr-2001" TYPE="STUDY">Komindr 2001</LINK>; <LINK REF="STD-Rizkalla-2004" TYPE="STUDY">Rizkalla 2004</LINK>; <LINK REF="STD-Wolever-1992" TYPE="STUDY">Wolever 1992</LINK>). They were conducted in Australia (<LINK REF="STD-Brand-1991" TYPE="STUDY">Brand 1991</LINK>; <LINK REF="STD-Gilbertson-2001" TYPE="STUDY">Gilbertson 2001</LINK>; <LINK REF="STD-Luscombe-1999" TYPE="STUDY">Luscombe 1999</LINK>), Canada (<LINK REF="STD-Wolever-1992" TYPE="STUDY">Wolever 1992</LINK>), France (<LINK REF="STD-Fontvieille-1992" TYPE="STUDY">Fontvieille 1992</LINK>; <LINK REF="STD-Rizkalla-2004" TYPE="STUDY">Rizkalla 2004</LINK>), Italy (<LINK REF="STD-Giacco-2000" TYPE="STUDY">Giacco 2000</LINK>) Mexico (<LINK REF="STD-Jimenez_x002d_Cruz-2003" TYPE="STUDY">Jimenez-Cruz 2003</LINK>) and UK (<LINK REF="STD-Frost-1994" TYPE="STUDY">Frost 1994</LINK>). The duration ranged from four weeks (<LINK REF="STD-Komindr-2001" TYPE="STUDY">Komindr 2001</LINK>; <LINK REF="STD-Luscombe-1999" TYPE="STUDY">Luscombe 1999</LINK>; <LINK REF="STD-Rizkalla-2004" TYPE="STUDY">Rizkalla 2004</LINK> ) to 52 weeks (<LINK REF="STD-Gilbertson-2001" TYPE="STUDY">Gilbertson 2001</LINK>). The maximum length of follow up was 12 months from the start of the intervention (<LINK REF="STD-Gilbertson-2001" TYPE="STUDY">Gilbertson 2001</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Participants</HEADING>
<P>The included studies involved a total of 402 participants. The number of participants ranged from 104 participants in a parallel trial (<LINK REF="STD-Gilbertson-2001" TYPE="STUDY">Gilbertson 2001</LINK>) to six participants in a crossover trial (<LINK REF="STD-Wolever-1992" TYPE="STUDY">Wolever 1992</LINK>). The mean age ranged from 10 (SD 2) years (<LINK REF="STD-Gilbertson-2001" TYPE="STUDY">Gilbertson 2001</LINK>) to 63 (SD 4) years (<LINK REF="STD-Wolever-1992" TYPE="STUDY">Wolever 1992</LINK>) and more males than females participated. There was a total of 247 participants in the six studies reporting percentage glycated haemoglobin included in the percentage glycated haemoglobin meta-analysis (<LINK REF="STD-Brand-1991" TYPE="STUDY">Brand 1991</LINK>; <LINK REF="STD-Giacco-2000" TYPE="STUDY">Giacco 2000</LINK>; <LINK REF="STD-Gilbertson-2001" TYPE="STUDY">Gilbertson 2001</LINK>; <LINK REF="STD-Jimenez_x002d_Cruz-2003" TYPE="STUDY">Jimenez-Cruz 2003</LINK>; <LINK REF="STD-Komindr-2001" TYPE="STUDY">Komindr 2001</LINK>; <LINK REF="STD-Rizkalla-2004" TYPE="STUDY">Rizkalla 2004</LINK>) and a total of 141 participants in the four studies reporting fructosamine included in the fructosamine meta-analysis (<LINK REF="STD-Fontvieille-1992" TYPE="STUDY">Fontvieille 1992</LINK>; <LINK REF="STD-Frost-1994" TYPE="STUDY">Frost 1994</LINK>; <LINK REF="STD-Luscombe-1999" TYPE="STUDY">Luscombe 1999</LINK>; <LINK REF="STD-Wolever-1992" TYPE="STUDY">Wolever 1992</LINK>). There were 14 participants in the trial reporting results as glycosylated albumin (<LINK REF="STD-Collier-1988" TYPE="STUDY">Collier 1988</LINK>). 209 of these participants received the low glycaemic index or load diet intervention. Two studies involved children (<LINK REF="STD-Collier-1988" TYPE="STUDY">Collier 1988</LINK>; <LINK REF="STD-Gilbertson-2001" TYPE="STUDY">Gilbertson 2001</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Interventions</HEADING>
<P>Ten studies compared a low glycaemic index diet with a higher glycaemic index diet (<LINK REF="STD-Brand-1991" TYPE="STUDY">Brand 1991</LINK>; <LINK REF="STD-Collier-1988" TYPE="STUDY">Collier 1988</LINK>; <LINK REF="STD-Fontvieille-1992" TYPE="STUDY">Fontvieille 1992</LINK>; <LINK REF="STD-Frost-1994" TYPE="STUDY">Frost 1994</LINK>; <LINK REF="STD-Giacco-2000" TYPE="STUDY">Giacco 2000</LINK>; <LINK REF="STD-Jimenez_x002d_Cruz-2003" TYPE="STUDY">Jimenez-Cruz 2003</LINK>; <LINK REF="STD-Komindr-2001" TYPE="STUDY">Komindr 2001</LINK>; <LINK REF="STD-Luscombe-1999" TYPE="STUDY">Luscombe 1999</LINK>; <LINK REF="STD-Rizkalla-2004" TYPE="STUDY">Rizkalla 2004</LINK>; <LINK REF="STD-Wolever-1992" TYPE="STUDY">Wolever 1992</LINK>). One study compared the low-GI diet to a diet using measured carbohydrate exchanges (<LINK REF="STD-Gilbertson-2001" TYPE="STUDY">Gilbertson 2001</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Duration of studies</HEADING>
<P>The low glycaemic index dietary interventions ranged from four weeks duration (<LINK REF="STD-Komindr-2001" TYPE="STUDY">Komindr 2001</LINK>; <LINK REF="STD-Luscombe-1999" TYPE="STUDY">Luscombe 1999</LINK>; <LINK REF="STD-Rizkalla-2004" TYPE="STUDY">Rizkalla 2004</LINK>) to 12 months (<LINK REF="STD-Gilbertson-2001" TYPE="STUDY">Gilbertson 2001</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcomes</HEADING>
<P>Original data can be found in <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK> and <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="5">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Glycaemic control</HEADING>
<P>Glycated haemoglobin:<I> </I>Seven of the included trials reported percentage glycated haemoglobin ( <LINK REF="STD-Brand-1991" TYPE="STUDY">Brand 1991</LINK>; <LINK REF="STD-Fontvieille-1992" TYPE="STUDY">Fontvieille 1992</LINK>; <LINK REF="STD-Giacco-2000" TYPE="STUDY">Giacco 2000</LINK>; <LINK REF="STD-Gilbertson-2001" TYPE="STUDY">Gilbertson 2001</LINK>; <LINK REF="STD-Jimenez_x002d_Cruz-2003" TYPE="STUDY">Jimenez-Cruz 2003</LINK>; <LINK REF="STD-Komindr-2001" TYPE="STUDY">Komindr 2001</LINK>; <LINK REF="STD-Rizkalla-2004" TYPE="STUDY">Rizkalla 2004</LINK>). One of these trials reported both percentage glycated haemoglobin and fructosamine results, hence as this trial had a duration of only five weeks, as per the protocol only the value for fructosamine was included in the meta-analysis (<LINK REF="STD-Fontvieille-1992" TYPE="STUDY">Fontvieille 1992</LINK>).</P>
<P>Fructosamine: Four trials (n=141) reported fructosamine (<LINK REF="STD-Fontvieille-1992" TYPE="STUDY">Fontvieille 1992</LINK>; <LINK REF="STD-Frost-1994" TYPE="STUDY">Frost 1994</LINK>; <LINK REF="STD-Luscombe-1999" TYPE="STUDY">Luscombe 1999</LINK>; <LINK REF="STD-Wolever-1992" TYPE="STUDY">Wolever 1992</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Adverse events</HEADING>
<P>Two<I> </I>trials reported adverse events or included the incidence of hypo- and hyperglycaemia in the outcomes (<LINK REF="STD-Giacco-2000" TYPE="STUDY">Giacco 2000</LINK>; <LINK REF="STD-Gilbertson-2001" TYPE="STUDY">Gilbertson 2001</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Insulin action (fasting plasma insulin, insulin sensitivity, insulin area under the curve, total insulin released/day, insulin-to-glucose ratio)</HEADING>
<P>Five studies included parameters related to insulin action as an outcome (<LINK REF="STD-Fontvieille-1992" TYPE="STUDY">Fontvieille 1992</LINK>; <LINK REF="STD-Giacco-2000" TYPE="STUDY">Giacco 2000</LINK>; <LINK REF="STD-Gilbertson-2001" TYPE="STUDY">Gilbertson 2001</LINK>; <LINK REF="STD-Luscombe-1999" TYPE="STUDY">Luscombe 1999</LINK>; <LINK REF="STD-Rizkalla-2004" TYPE="STUDY">Rizkalla 2004</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Morbidity (diabetes and cardiovascular related morbidity, like angina pectoris, myocardial infarction, stroke, peripheral vascular disease, neuropathy, retinopathy, nephropathy, erectile dysfunction, amputation)</HEADING>
<P>No trial included morbidity as outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Quality of life (using a validated instrument)</HEADING>
<P>One trial included quality of life as an outcome (<LINK REF="STD-Gilbertson-2001" TYPE="STUDY">Gilbertson 2001</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Costs</HEADING>
<P>No trial included costs as an outcome</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Mortality</HEADING>
<P>No trial included mortality as an outcome.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2008-11-06 14:47:50 +0100" MODIFIED_BY="Bernd Richter">
<P>Studies which were excluded not at the time of the literature search, but after the entire papers had been perused and the reasons for their exclusion are given in the table <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-11-12 11:35:28 +0100" MODIFIED_BY="Bernd Richter">
<P>For details see <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>.</P>
<ALLOCATION MODIFIED="2008-11-06 14:49:56 +0100" MODIFIED_BY="Bernd Richter">
<P>While all included trials were described as randomised, only one included trial reported the method of randomisation, through the use of random number tables ( <LINK REF="STD-Frost-1994" TYPE="STUDY">Frost 1994</LINK>).</P>
</ALLOCATION>
<EXCLUSIONS MODIFIED="2008-11-06 16:25:23 +0100" MODIFIED_BY="Bernd Richter">
<P>Most studies described losses to follow-up or dropouts, if any occurred in the study. There were no dropouts in six trials (<LINK REF="STD-Brand-1991" TYPE="STUDY">Brand 1991</LINK>; <LINK REF="STD-Collier-1988" TYPE="STUDY">Collier 1988</LINK>; <LINK REF="STD-Fontvieille-1992" TYPE="STUDY">Fontvieille 1992</LINK>; <LINK REF="STD-Komindr-2001" TYPE="STUDY">Komindr 2001</LINK>; <LINK REF="STD-Rizkalla-2004" TYPE="STUDY">Rizkalla 2004</LINK>; <LINK REF="STD-Wolever-1992" TYPE="STUDY">Wolever 1992</LINK>). Dropouts were encountered in the other five trials (<LINK REF="STD-Frost-1994" TYPE="STUDY">Frost 1994</LINK>; <LINK REF="STD-Giacco-2000" TYPE="STUDY">Giacco 2000</LINK>; <LINK REF="STD-Gilbertson-2001" TYPE="STUDY">Gilbertson 2001</LINK>; <LINK REF="STD-Jimenez_x002d_Cruz-2003" TYPE="STUDY">Jimenez-Cruz 2003</LINK>; <LINK REF="STD-Luscombe-1999" TYPE="STUDY">Luscombe 1999</LINK>) and reasons for the dropouts were described in four of these trials (<LINK REF="STD-Frost-1994" TYPE="STUDY">Frost 1994</LINK>; <LINK REF="STD-Gilbertson-2001" TYPE="STUDY">Gilbertson 2001</LINK>; <LINK REF="STD-Jimenez_x002d_Cruz-2003" TYPE="STUDY">Jimenez-Cruz 2003</LINK>; <LINK REF="STD-Luscombe-1999" TYPE="STUDY">Luscombe 1999</LINK>). One study, with nine dropouts, did not give reasons (<LINK REF="STD-Giacco-2000" TYPE="STUDY">Giacco 2000</LINK>).<BR/>
</P>
</EXCLUSIONS>
<OTHER_BIAS_SOURCES MODIFIED="2008-11-06 14:50:07 +0100" MODIFIED_BY="Bernd Richter">
<P>No trial included in the review reported any significant differences between groups in the main characteristics of participants at baseline.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-11-21 11:06:31 +0100" MODIFIED_BY="Bernd Richter">
<SUBSECTION>
<HEADING LEVEL="3">Glycaemic index of the intervention and control group diets</HEADING>
<P>The glycaemic index (GI) of the low-GI diet in the <LINK REF="STD-Brand-1991" TYPE="STUDY">Brand 1991</LINK> study was 15% lower than that of the high-GI diet (77 ± 3 SE versus 91 ± 3, P &lt; 0.01). The mean GI for the low-GI diet was 12 units lower than the control high-GI diet in the <LINK REF="STD-Collier-1988" TYPE="STUDY">Collier 1988</LINK> study (68 ± 3 SE versus 82 ± 1 units P &lt; 0.005), and this change was achieved by exchanging approximately 50% of the carbohydrates coming from high-GI foods for low-GI foods. In the <LINK REF="STD-Fontvieille-1992" TYPE="STUDY">Fontvieille 1992</LINK> study, 38 ± 5% SD was the GI for the low-GI diet, while the GI for the high-GI diet was 64 ± 2%, P &lt; 0.001. The GI of the low-GI diet in the <LINK REF="STD-Frost-1994" TYPE="STUDY">Frost 1994</LINK> study was 77 ± 1% SEM, while the GI of the high-GI diet was 82 ± 1%, P &lt; 0.01. The average GI of the two diets was also different in the <LINK REF="STD-Giacco-2000" TYPE="STUDY">Giacco 2000</LINK> study, where the intervention diet had a GI of 70% and the control diet had a GI of 90%. In the <LINK REF="STD-Gilbertson-2001" TYPE="STUDY">Gilbertson 2001</LINK> study, in which the participants were all children with type 1 diabetes (n = 104) the low-GI diet, which was designed to be flexible, was compared to a measured carbohydrate exchange diet. Both the GI and the glycaemic load (GL) of the low-GI diet were significantly lower the the high-GI diet for the <LINK REF="STD-Jimenez_x002d_Cruz-2003" TYPE="STUDY">Jimenez-Cruz 2003</LINK> study (P = 0.0001). In the <LINK REF="STD-Komindr-2001" TYPE="STUDY">Komindr 2001</LINK> study, the GI of the low-GI diet versus the high-GI diet was approximately 70 versus 100 GI units. The GI of the low-GI diet was 20 units lower than that of the high-GI diet in the <LINK REF="STD-Luscombe-1999" TYPE="STUDY">Luscombe 1999</LINK> study (43 GI units versus 63 GI units). The low-GI diet had a GI of 58 compared with 86 for the high-GI diet in the <LINK REF="STD-Wolever-1992" TYPE="STUDY">Wolever 1992</LINK> study.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Glycaemic control</HEADING>
<P>Pooled data from the six studies reporting glycated haemoglobin A1c (HbA1c) with participants whose glycated haemoglobin was not yet optimised (<LINK REF="STD-Brand-1991" TYPE="STUDY">Brand 1991</LINK>; <LINK REF="STD-Giacco-2000" TYPE="STUDY">Giacco 2000</LINK>; <LINK REF="STD-Gilbertson-2001" TYPE="STUDY">Gilbertson 2001</LINK>; <LINK REF="STD-Jimenez_x002d_Cruz-2003" TYPE="STUDY">Jimenez-Cruz 2003</LINK>; <LINK REF="STD-Komindr-2001" TYPE="STUDY">Komindr 2001</LINK>; <LINK REF="STD-Rizkalla-2004" TYPE="STUDY">Rizkalla 2004</LINK>) showed that there was a significant decrease in HbA1c levels, indicating improved glycaemic control (WMD -0.5 % HbA1c, 95% CI -0.8 to -0.2, P = 0.001). When parallel and cross-over trials were analysed separately, pooled effect estimates remained stable: In the HbA1c parallel group of trials (<LINK REF="STD-Giacco-2000" TYPE="STUDY">Giacco 2000</LINK> and <LINK REF="STD-Gilbertson-2001" TYPE="STUDY">Gilbertson 2001</LINK>) the WMD was  -0.5% with a 95% CI of - 0.9 to -0.1, P = 0.02; and in the cross-over group of trials the WMD was -0.5% with a 95%CI of -1.0 to -0.1, P = 0.03</P>
<P>Considering the studies individually, in the study comparing the low glycaemic index diet with the carbohydrate exchange diet, by 12 months the mean difference in HbA1c levels between the groups was not significant (P = 0.05), however twice as many participants in the low GI group (45%) attained acceptable HbA1c levels compared with only 22% of participants in the carbohydrate exchange group (P = 0.02 after adjustment for baseline values) (<LINK REF="STD-Gilbertson-2001" TYPE="STUDY">Gilbertson 2001</LINK>).<BR/>Percentage HbA1c was also significantly lower after the low-GI diet compared to after the high-GI diet in the <LINK REF="STD-Jimenez_x002d_Cruz-2003" TYPE="STUDY">Jimenez-Cruz 2003</LINK> study (P &lt; 0.02), in the <LINK REF="STD-Giacco-2000" TYPE="STUDY">Giacco 2000</LINK> study (P &lt; 0.05), in the <LINK REF="STD-Brand-1991" TYPE="STUDY">Brand 1991</LINK> study (P &lt; 0.05) and in the <LINK REF="STD-Rizkalla-2004" TYPE="STUDY">Rizkalla 2004</LINK> study (P &lt; 0.05). In the <LINK REF="STD-Rizkalla-2004" TYPE="STUDY">Rizkalla 2004</LINK> study, the reduction in the<I> change</I> in HbA1c after the low-GI diet was also significantly more than after the high-GI diet (P &lt; 0.01).<BR/>
</P>
<P>One study which had a 12 week intervention reported the main outcome as fructosamine (<LINK REF="STD-Frost-1994" TYPE="STUDY">Frost 1994</LINK>). The three studies with an intervention duration of 4 to 6 weeks also reported results as fructosamine (<LINK REF="STD-Fontvieille-1992" TYPE="STUDY">Fontvieille 1992</LINK>; <LINK REF="STD-Luscombe-1999" TYPE="STUDY">Luscombe 1999</LINK>; <LINK REF="STD-Wolever-1992" TYPE="STUDY">Wolever 1992</LINK>), WMD -0.20 mmol/L (95% CI -0.46 to 0.07, P = 0.14).</P>
<P>Considering these studies individually, in the <LINK REF="STD-Fontvieille-1992" TYPE="STUDY">Fontvieille 1992</LINK> study, the reduction in fructosamine with the low-GI diet was significant compared to the high-GI diet (3.9 ± 0.9 versus 3.4 ± 0.4, mmol/L, P &lt; 0.05). In the parallel <LINK REF="STD-Frost-1994" TYPE="STUDY">Frost 1994</LINK> study, the within-group change in fructosamine levels, which decreased in the low-GI diet group but not in the high-GI diet group, was also significant (P &lt; 0.05). The <LINK REF="STD-Wolever-1992" TYPE="STUDY">Wolever 1992</LINK> study reported that serum fructosamine fell significantly after the low-GI diet, with no change after the high-GI diet (P &lt; 0.05).<BR/>
<BR/>Glycosylated albumin levels decreased significantly in the low glycaemic index intervention, but not in the high glycaemic intervention in the one study reporting this outcome (low glycaemic index diet 13.2 ± 1.5 % to 10.7 ± 2.2 %, P &lt; 0.05; high glycaemic index diet 13.1 ± 2.3 % to 14.6 ± 1.9 %, not significant) (<LINK REF="STD-Collier-1988" TYPE="STUDY">Collier 1988</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse effects</HEADING>
<P>Two trials reported on hypo- or hyperglycaemic events, but did not give further infomation on whether they were mild/moderate or severe (<LINK REF="STD-Giacco-2000" TYPE="STUDY">Giacco 2000</LINK>; <LINK REF="STD-Gilbertson-2001" TYPE="STUDY">Gilbertson 2001</LINK>). In the meta-analysis for episodes of hypoglycaemia, there was heterogeneity (I<SUP>2 </SUP>= 50.8%) and so the results for the two studies are reported separately: In one study, where the control diet was a higher GI diet, episodes of hypoglycaemia were significantly fewer with the low-GI diet compared to the control diet (mean difference -0.8 episodes per patient per month, P &lt; 0.01) (<LINK REF="STD-Giacco-2000" TYPE="STUDY">Giacco 2000</LINK>). In the second study, where the control diet was a measured carbohydrate exchange diet in children with type 1 diabetes, the proportion of participants reporting more than 15 episodes of hyperglycaemia per month was significantly lower for the low-GI diet group compared to the measured carbohydrate exchange group, (35% versus 66%, P = 0.006 after adjustment for baseline values) at 12 months (<LINK REF="STD-Gilbertson-2001" TYPE="STUDY">Gilbertson 2001</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Insulin action</HEADING>
<P>Five included studies reported on parameters related to insulin action (<LINK REF="STD-Fontvieille-1992" TYPE="STUDY">Fontvieille 1992</LINK>; <LINK REF="STD-Giacco-2000" TYPE="STUDY">Giacco 2000</LINK>; <LINK REF="STD-Gilbertson-2001" TYPE="STUDY">Gilbertson 2001</LINK>; <LINK REF="STD-Luscombe-1999" TYPE="STUDY">Luscombe 1999</LINK>; <LINK REF="STD-Rizkalla-2004" TYPE="STUDY">Rizkalla 2004</LINK>).</P>
<P>Whole body peripheral insulin sensitivity, measured by euglycaemic-hyperinsulinaemic clamp, was significantly higher after the low-GI diet than after the high-GI diet (glucose disposal: 7.0 ± 1.3 versus 4.8 ± 0.9 mg glucose/kg/min, P &lt; 0.001)(<LINK REF="STD-Rizkalla-2004" TYPE="STUDY">Rizkalla 2004</LINK>).</P>
<P>Another study reported that no significant differences were found in insulin or drug requirements, or in insulin binding to erythrocytes (<LINK REF="STD-Fontvieille-1992" TYPE="STUDY">Fontvieille 1992</LINK>). In the two studies reporting insulin dose, both found no significant differences (<LINK REF="STD-Giacco-2000" TYPE="STUDY">Giacco 2000</LINK>; <LINK REF="STD-Gilbertson-2001" TYPE="STUDY">Gilbertson 2001</LINK>). There were also no significant differences reported in plasma insulin levels between groups (<LINK REF="STD-Luscombe-1999" TYPE="STUDY">Luscombe 1999</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Morbidity</HEADING>
<P>No study reported on morbidity.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Quality of life (using a validated instrument)</HEADING>
<P>One trial, in children, reported on quality of life and found that it was significantly influenced by the type of diet (<LINK REF="STD-Gilbertson-2001" TYPE="STUDY">Gilbertson 2001</LINK>), although validation measures for the questionnaire were not reported. In this trial, twice as many parents in the low-GI group stated that their child had no difficulties in selecting their own meals at the 12-month time point (51% versus 24%, P = 0.01). Almost twice as many parents from the low-GI group also reported that diabetes never limited the type of family activities pursued (53% versus 27%, P = 0.02).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Costs</HEADING>
<P>No study reported on costs.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Mortality</HEADING>
<P>No study reported on mortality.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Heterogeneity</HEADING>
<P>There was heterogeneity in the adverse events results for episodes of hypoglycaemia. In the meta-analysis for episodes of hypoglycaemia, as there was heterogeneity (I<SUP>2</SUP> = 50.8%), the results for the two studies have been reported separately. In one study, where the control diet was a higher GI diet, episodes of hypoglycaemia were significantly fewer with the low-GI diet compared to the control diet (WMD -0.8 episodes, 95% CI -1.3 to -0.3, P &lt; 0.01) (<LINK REF="STD-Giacco-2000" TYPE="STUDY">Giacco 2000</LINK>). In the second study, the control diet was a measured carbohydrate exchange diet in children with type 1 diabetes and there was no difference reported in hypoglycaemic episodes (<LINK REF="STD-Gilbertson-2001" TYPE="STUDY">Gilbertson 2001</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Subgroup analysis</HEADING>
<P>Not performed due to the small number of included studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Sensitivity analysis</HEADING>
<P>The results were substantially unaffected by omitting individual studies from the analysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Assessment of publication bias</HEADING>
<P>There were too few studies for detailed analysis of the funnel plot.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Follow-up</HEADING>
<P>One study reported results at 12 month follow-up from the commencement of the study, reporting that rates of excessive hyperglycaemia (&gt;15 episodes per month) were significantly lower in the low-GI group (35 versus 66%, P = 0.006) (<LINK REF="STD-Gilbertson-2001" TYPE="STUDY">Gilbertson 2001</LINK>).</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-11-12 11:03:02 +0100" MODIFIED_BY="Bernd Richter">
<SUMMARY_OF_RESULTS MODIFIED="2008-11-12 11:03:02 +0100" MODIFIED_BY="Bernd Richter">
<P>This review indicates that glycaemic control in people with diabetes improved significantly with a low glycaemic index diet, compared to those on higher glycaemic index diets or measured carbohydrate exchange diets. The decrease of 0.5% glycated haemoglobin A1c (HbA1c) is clinically significant and is similar to decreases achieved through medications for newly diagnosed type 2 diabetes ( <LINK REF="REF-Holman-1999" TYPE="REFERENCE">Holman 1999</LINK>; <LINK REF="REF-UK-PDSG-1995" TYPE="REFERENCE">UK PDSG 1995</LINK>). Improvements of this size have been associated with a significant reduction in the risk of microvascular complications (<LINK REF="REF-Stratton-2000" TYPE="REFERENCE">Stratton 2000</LINK>). The UK Prospective Diabetes Study Group (UKPDSG) found that each 1% reduction in glycated haemoglobin was associated with a reduction in risk of 21% (95% confidence interval (CI) 17% to 24%, P &lt; 0.0001) for any end point related to diabetes and a reduction in risk of 37% (95% CI 33% to 41%, P &lt; 0.0001) for microvascular complications and that any reduction in glycated haemoglobin is likely to reduce the risk of complications (<LINK REF="REF-Stratton-2000" TYPE="REFERENCE">Stratton 2000</LINK>).</P>
<P>Of additional clinical significance, improved glycaemic control was also associated with a decrease in adverse outcomes, namely hypoglycaemic episodes. In the two trials that reported this outcome, improved glycated haemoglobin was associated with a reduction in hypoglycaemic events with the low-GI diet compared to a high-GI diet in one trial (<LINK REF="STD-Giacco-2000" TYPE="STUDY">Giacco 2000</LINK>), and in the other trial, the proportion of participants reporting more than 15 hyperglycaemic episodes per month was lower for the low-GI diet compared to a measured carbohydrate exchange diet (<LINK REF="STD-Gilbertson-2001" TYPE="STUDY">Gilbertson 2001</LINK>).</P>
<P>Considering each of the studies individually, the improvement in glycaemic control in people on low-GI diets versus other diets reached statistical significance in nine of the individual included studies: five which were reporting HbA1c (<LINK REF="STD-Brand-1991" TYPE="STUDY">Brand 1991</LINK>; <LINK REF="STD-Giacco-2000" TYPE="STUDY">Giacco 2000</LINK>; <LINK REF="STD-Gilbertson-2001" TYPE="STUDY">Gilbertson 2001</LINK>; <LINK REF="STD-Jimenez_x002d_Cruz-2003" TYPE="STUDY">Jimenez-Cruz 2003</LINK>; <LINK REF="STD-Rizkalla-2004" TYPE="STUDY">Rizkalla 2004</LINK>), three reporting fructosamine (<LINK REF="STD-Fontvieille-1992" TYPE="STUDY">Fontvieille 1992</LINK>; <LINK REF="STD-Frost-1994" TYPE="STUDY">Frost 1994</LINK>; <LINK REF="STD-Wolever-1992" TYPE="STUDY">Wolever 1992</LINK>) and one reporting per cent glycosylated albumin (<LINK REF="STD-Collier-1988" TYPE="STUDY">Collier 1988</LINK>). The meta-analysis confirmed these results.<BR/>
<BR/>Of the eleven studies included in this review, three studies had participants with type 1 diabetes (<LINK REF="STD-Collier-1988" TYPE="STUDY">Collier 1988</LINK>, <LINK REF="STD-Giacco-2000" TYPE="STUDY">Giacco 2000</LINK>; <LINK REF="STD-Gilbertson-2001" TYPE="STUDY">Gilbertson 2001</LINK>), seven with type 2 diabetes (<LINK REF="STD-Brand-1991" TYPE="STUDY">Brand 1991</LINK>; <LINK REF="STD-Frost-1994" TYPE="STUDY">Frost 1994</LINK>; <LINK REF="STD-Jimenez_x002d_Cruz-2003" TYPE="STUDY">Jimenez-Cruz 2003</LINK>; <LINK REF="STD-Komindr-2001" TYPE="STUDY">Komindr 2001</LINK>; <LINK REF="STD-Rizkalla-2004" TYPE="STUDY">Rizkalla 2004</LINK>; <LINK REF="STD-Wolever-1992" TYPE="STUDY">Wolever 1992</LINK>) and one study had participants with either type 1 or type 2 (<LINK REF="STD-Fontvieille-1992" TYPE="STUDY">Fontvieille 1992</LINK>). Two studies involved children, all of whom had type 1 diabetes (<LINK REF="STD-Collier-1988" TYPE="STUDY">Collier 1988</LINK>; <LINK REF="STD-Gilbertson-2001" TYPE="STUDY">Gilbertson 2001</LINK>).</P>
<P>One excluded study reported that there was a greater reduction in the change in percentage glycated haemoglobin after the low-GI diet compared to that after the high-GI diet (-0.3% HbA1c) (<LINK REF="STD-Heilbronn-2002" TYPE="STUDY">Heilbronn 2002</LINK>). This study was excluded from this review because participants were of unknown diabetic status at the start of the intervention (diabetic or improved diabetic), only having been diagnosed as having type 2 diabetes during some time in the previous ten years.</P>
<P>In the <LINK REF="STD-Wolever-2008" TYPE="STUDY">Wolever 2008</LINK> study, participants commenced the study with already optimised HbA1c levels (6.2 ± 1% HbA1c) and hence this study was also excluded, since the effect of the diets on HbA1c was our primary outcome. This study found, however, that there were sustained reductions in both postprandial glucose and C-reactive protein on the low-GI diet, also indicating that it could be beneficial in the ongoing management of type 2 diabetes.</P>
<P>In another excluded study, in which medications were adjusted as necessary, significantly less diabetic medication was required in people on the low glycaemic index diet, compared to the ADA diet, to achieve equivalent control of HbA1c levels (<LINK REF="STD-Ma-2008" TYPE="STUDY">Ma 2008</LINK>).</P>
<P>Insulin sensitivity was affected by the glycaemic index of the diet, with a significant increase in the whole body peripheral insulin sensitivity, measured via euglycaemic-hyperinsulinaemic clamp after the low-GI diet compared to the high-GI diet (<LINK REF="STD-Rizkalla-2004" TYPE="STUDY">Rizkalla 2004</LINK>).</P>
<P>All studies in the review compared the low glycaemic index diet with a high glycaemic index diet, except for one study in which the comparison diet was a measured carbohydrate exchange diet (<LINK REF="STD-Gilbertson-2001" TYPE="STUDY">Gilbertson 2001</LINK>). In this study comparing the low-GI diet to a restricted carbohydrate exchange diet, involving children with type 1 diabetes (<LINK REF="STD-Gilbertson-2001" TYPE="STUDY">Gilbertson 2001</LINK>), twice as many participants in the low-GI group reached acceptable HbA1c levels at 12 months without any increase in the rate of hypoglycaemic occurrences, compared to the carbohydrate exchange group. Hence, even when compared to the restricted carbohydrate exchange diet, the low glycaemic index diet showed greater improvement in glycaemic control.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2008-11-06 16:45:49 +0100" MODIFIED_BY="Bernd Richter">
<P>This review suggests that a low-GI diet is beneficial for improving glycaemic control in people with diabetes, and that a low-GI diet is associated with a decrease in the number of hypoglycaemic episodes. Participants in the included trials were both adults and children with diabetes, suggesting that the results would be relevant to a broad spectrum of age groups in other similar communities. Inclusion criteria for studies were either type 1 or type 2 diabetes, or both, and hence the results of the review have relevance to both types of diabetes. None of the trials occurred in developing countries.</P>
</APPLICABILITY_OF_FINDINGS>
<POTENTIAL_BIASES MODIFIED="2008-11-06 14:52:54 +0100" MODIFIED_BY="Bernd Richter">
<P>Eleven relevant studies were identified, all of which were randomised controlled trials. Some methodological limitations were present such as failure to conceal allocation and lack of reporting on blinding of outcome assessors.<B> </B>
</P>
</POTENTIAL_BIASES>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2008-11-12 11:40:06 +0100" MODIFIED_BY="Bernd Richter">
<IMPLICATIONS_PRACTICE MODIFIED="2008-11-12 11:03:54 +0100" MODIFIED_BY="Bernd Richter">
<P>The studies included in this systematic review were all randomised controlled trials, and all had interventions of at least four weeks or longer. The longest trial was 12 months. This review provides data that low glycaemic index diets can significantly improve diabetic control in less than optimally controlled people with diabetes by lowering percentage glycated haemoglobin A1c (HbA1c) levels by 0.5%. This is clinically significant and comparable to decreases achieved through medications for newly diagnosed type 2 diabetes (<LINK REF="REF-Holman-1999" TYPE="REFERENCE">Holman 1999</LINK>; <LINK REF="REF-UK-PDSG-1995" TYPE="REFERENCE">UK PDSG 1995</LINK>). The UK Prospective Diabetes Study Group found that 1% reduction in glycated haemoglobin was associated with reductions in risk of 21% for any end point related to diabetes and a reduction in risk of 37% for microvascular complications and that any reduction in glycated haemoglobin is likely to reduce the risk of complications (<LINK REF="REF-Stratton-2000" TYPE="REFERENCE">Stratton 2000</LINK>). Importantly, reduction in glycated haemoglobin with the low-GI diet was associated with decreased risk of hypoglycaemic episodes. When compared with a high-GI diet, the low-GI diet reduced hypoglycaemic events significantly (<LINK REF="STD-Giacco-2000" TYPE="STUDY">Giacco 2000</LINK>). Similarly, the proportion of participants reporting more than 15 hyperglycaemic episodes per month was significantly lower for the low-GI diet compared to the measured carbohydrate exchange diet (<LINK REF="STD-Gilbertson-2001" TYPE="STUDY">Gilbertson 2001</LINK>).</P>
<P>Whole body peripheral insulin sensitivity, measured via euglycaemic-hyperinsulinaemic clamp, was also significantly affected by the glycaemic index of the diet, significantly increasing in the low-GI group compared to the high-GI group (<LINK REF="STD-Rizkalla-2004" TYPE="STUDY">Rizkalla 2004</LINK>). The improvement may benefit the patient with diabetes by lessening or even avoiding the requirement for medication.</P>
<P>Hence, lowering the glycaemic index of foods in the diet appears to be an effective method of improving glycaemic control in diabetes without compromising the number of hypoglycaemic episodes.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2008-11-12 11:40:06 +0100" MODIFIED_BY="Bernd Richter">
<P>While one study provided follow-up data at 12 months after the start of the intervention, it would be useful if further long-range studies could be performed, including quality of life outcomes with validated instruments to determine the acceptability of incorporating a low-GI diet in a person's lifestyle, as well as measurement of long-term glycaemic control. There are indications that the improvement can be maintained, as an excluded study reported that at 12 months, there was no significant change in HbA1c levels which had already been optimised before the commencement of the study (<LINK REF="STD-Wolever-2008" TYPE="STUDY">Wolever 2008</LINK>). There were two studies in children, all of whom had type 1 diabetes, and further longer range studies with children would be useful to confirm the impact of low glycaemic index diets on long-term glycaemic control, adverse events and quality of life.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>Professor Chris Cowell, The University of Sydney, Head of Endocrinology at The Children's Hospital at Westmead, for expert advice on clinical aspects; Samantha Clarke, Acting Head Diabetes Dietitian, The Children's Hospital at Westmead, for assistance in trial searching and Sunita Chauhan for assistance in search strategy development.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>DIANA THOMAS: conceived the idea for the review, designed and co-ordinated the review, developed the protocol, searched for trials, screened search results, assessed trial quality, extracted and entered data, analysed and interpreted data, developed the review.</P>
<P>ELIZABETH ELLIOTT: screened search results, assessed trials for quality, analysed and interpreted data, provided clinical perspective, developed the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-11-06 15:00:43 +0100" MODIFIED_BY="Bernd Richter">
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Brand-1991" NAME="Brand 1991" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brand JC, Colagiuri S, Crossman S, Allen A, Roberts DC and Truswell AS</AU>
<TI>Low-glycemic index foods improve long-term glycemic control in NIDDM</TI>
<SO>Diabetes Care</SO>
<YR>1991</YR>
<VL>14</VL>
<NO>2</NO>
<PG>95-101</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Collier-1988" NAME="Collier 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Collier GR, Giudici S, Kalmusky J, Wolever TM, Helman G, Wesson V, Ehrlich RM Jenkins DJ</AU>
<TI>Low glycemic index starchy foods improve glucose control and lower serum cholesterol in diabetic children</TI>
<SO>Diabetes Nutrition and Metabolism</SO>
<YR>1988</YR>
<VL>1</VL>
<PG>11-19</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fontvieille-1992" NAME="Fontvieille 1992" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fontvieille AM, Rizkalla SW, Penfornis A, Acosta M, Bornet FR, and Slama G</AU>
<TI>The use of low glycaemic index foods improves metabolic control of diabetic patients over five weeks</TI>
<SO>Diabetic Medicine</SO>
<YR>1992</YR>
<VL>9</VL>
<PG>444-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Frost-1994" NAME="Frost 1994" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Frost G, Wilding J and Beecham J</AU>
<TI>Dietary advice based on the glycaemic index improves dietary profile and metabolic control in type 2 diabetic patients</TI>
<SO>Diabetic Medicine</SO>
<YR>1994</YR>
<VL>11</VL>
<PG>397-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Giacco-2000" NAME="Giacco 2000" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Giacco R, Parillo M, Rivellese A, Lasorella G, Giacco A, D'Episcopo L, and Riccardi G</AU>
<TI>Long-term dietary treatment with increased amounts of fiber-rich low-glycemic index natural foods improves blood glucose control and reduces the number of hypoglycemic events in type 1 diabetic patients</TI>
<SO>Diabetes Care</SO>
<YR>2000</YR>
<VL>23</VL>
<PG>1461-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gilbertson-2001" NAME="Gilbertson 2001" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gilbertson H, Brand-Miller J, Thorburn A, Evans S, Chondros P, Werther G</AU>
<TI>The effect of flexible low glycemic index dietary advice versus measured carbohydrate exchange diets on glycemic control in children with type 1 diabetes</TI>
<SO>Diabetes Care</SO>
<YR>2001</YR>
<VL>24</VL>
<PG>1137-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jimenez_x002d_Cruz-2003" NAME="Jimenez-Cruz 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jimenez-Cruz A ; Bacardi-Gascon M; Turnbull WH; Rosales-Garay P; Severino-Lugo I</AU>
<TI>A Flexible, Low-Glycemic Index Mexican-Style Diet in Overweight and Obese Subjects With Type 2 Diabetes Improves Metabolic Parameters During a 6-Week Treatment Period</TI>
<SO>Diabetes Care</SO>
<YR>2003</YR>
<VL>26</VL>
<PG>1967-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Komindr-2001" NAME="Komindr 2001" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Komindr S, Ingsriswang S, Lerdvuthisopon N, Boontawee A</AU>
<TI>Effect of long-term intake of Asian food with different glycemic indices on diabetic control and protein conservation in type 2 diabetic patients</TI>
<SO>Journal of the Medical Association of Thailand</SO>
<YR>2001</YR>
<VL>84</VL>
<PG>85-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Luscombe-1999" NAME="Luscombe 1999" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Luscombe ND, Noakes M, Clifton PM</AU>
<TI>Diets high and low in glycemic index versus high monounsaturated fat diets: effects on glucose and lipid metabolism in NIDDM</TI>
<SO>European Journal of Clinical Nutrition</SO>
<YR>1999</YR>
<VL>53</VL>
<PG>473-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rizkalla-2004" NAME="Rizkalla 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rizkalla SW; Taghrid L; Laromiguiere M; Huet D; Boillot J; Rigoir A; Elgrably F; Slama</AU>
<TI>Improved Plasma Glucose Control, Whole-Body Glucose Utilization, and Lipid Profile on a Low-Glycemic Index Diet in Type 2 Diabetic Men: A randomized controlled trial</TI>
<SO>Diabetes Care</SO>
<YR>2004</YR>
<VL>27</VL>
<PG>1866-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wolever-1992" NAME="Wolever 1992" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wolever TM, Jenkins DJ, Vuksan V, Jenkins AL, Wong GS and Josse RG</AU>
<TI>Beneficial effect of low-glycemic index diet in overweight NIDDM subjects</TI>
<SO>Diabetes Care</SO>
<YR>1992</YR>
<VL>15</VL>
<PG>562-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Heilbronn-2002" NAME="Heilbronn 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heilbronn LK, Noakes M and Clifton PM</AU>
<TI>The Effect of High- and Low-Glycemic Index Energy Restricted Diets on Plasma Lipid and Glucose Profiles in Type 2 Diabetic Subjects with Varying Glycemic Control</TI>
<SO>Journal of the American College of Nutrition</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>120-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jarvi-1999" NAME="Jarvi 1999" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jarvi A, Karlstrom B, Granfeldt Y, Bjorck I, Asp N, Vessby B 1999</AU>
<TI>Improved glycemic control and lipid profile and normalized fibrinolytic activity on a low-glycemic index diet in type 2 diabetic patients</TI>
<SO>Diabetes Care</SO>
<YR>1999</YR>
<VL>22</VL>
<PG>10-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jenkins-1988" NAME="Jenkins 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jenkins DJ, Wolever TM, Buckley G, Lam KY, Giudici S, Kalmusky J, Jenkins AL, Patten RL, Bird J, Wong GS</AU>
<TI>Low-glycemic-index starchy foods in the diabetic diet</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>1988</YR>
<VL>48</VL>
<PG>248-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lafrance-1998" NAME="Lafrance 1998" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lafrance L, Rabasa-Lhoret R, Poisson D, Ducros F, and Chiasson JL</AU>
<TI>Effects of different glycaemic index foods and dietary fibre intake on glycaemic control in type 1 diabetic patients on intensive insulin therapy</TI>
<SO>Diabetic Medicine</SO>
<YR>1998</YR>
<VL>15</VL>
<NO>11</NO>
<PG>972-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ma-2008" NAME="Ma 2008" YEAR="2008">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ma Y; Olendzki BC; Merriam PA; Chiriboga DE; Culver AL et al</AU>
<TI>A randomized clinical trial comparing low-glycemic index versus ADA dietary education among individuals with type 2 diabetes</TI>
<SO>Nutrition</SO>
<YR>2007</YR>
<VL>24</VL>
<PG>45-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wolever-1992-b" NAME="Wolever 1992 b" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wolever TMS, Jenkins DJA, Vuskan V, Jenkins AL, Buckley GC, Wong GS and Josse RG</AU>
<TI>Beneficial effect of a low glycaemic index diet in type 2 diabetes</TI>
<SO>Diabetic Medicine</SO>
<YR>1992</YR>
<VL>9</VL>
<PG>451-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wolever-2008" NAME="Wolever 2008" YEAR="2008">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wolever TMS; Gibbs AL; Mehling C; Chiasson JL; Connelly PW; Josse RG et al</AU>
<TI>The Canadian Trial of Carbohydrates in Diabetes (CCD), a 1-y controlled trial of low-glycemic-index dietary carbohydrate in type 2 diabetes: no effect on glycated hemoglobin but reduction in C-reactive protein</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2008</YR>
<VL>87</VL>
<PG>114-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-11-06 15:00:43 +0100" MODIFIED_BY="Bernd Richter">
<ADDITIONAL_REFERENCES MODIFIED="2008-11-06 15:00:43 +0100" MODIFIED_BY="Bernd Richter">
<REFERENCE ID="REF-ADA--2004" NAME="ADA  2004" TYPE="JOURNAL_ARTICLE">
<AU>Goldstein DE, Little RR, Lorenz RA, Malone JI, Nathan DM, Peterson CM</AU>
<TI>Tests of Glycemia in Diabetes</TI>
<SO>Diabetes Care</SO>
<YR>2004</YR>
<VL>27</VL>
<NO>1 Suppl</NO>
<PG>S91-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ADA-2008" NAME="ADA 2008" TYPE="JOURNAL_ARTICLE">
<AU>American Diabetes Association</AU>
<TI>Nutrition recommendations and interventions for diabetes</TI>
<SO>Diabetes Care</SO>
<YR>2008</YR>
<VL>31</VL>
<PG>S61-78</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brand_x002d_Miller-2003" NAME="Brand-Miller 2003" TYPE="JOURNAL_ARTICLE">
<AU>Brand-Miller J, Hayne S, Petocz P, Colagiuri S</AU>
<TI>Low-Glycemic Index Diets in the Management of Diabetes</TI>
<SO>Diabetes Care</SO>
<YR>2003</YR>
<VL>26</VL>
<NO>8</NO>
<PG>2261-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cohen-1960" MODIFIED="2008-11-06 12:33:10 +0100" MODIFIED_BY="Bernd Richter" NAME="Cohen 1960" TYPE="BOOK_SECTION">
<AU>Cohen J</AU>
<TI>A coefficient of agreement for nominal scales</TI>
<SO>Educational and Psychological Measurement</SO>
<YR>1960</YR>
<PB>37-46</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cooper-1994" NAME="Cooper 1994" TYPE="BOOK">
<AU>Cooper H, Hedges LV</AU>
<SO>The handbook of research synthesis</SO>
<YR>1994</YR>
<PB>NewYork: Russell Safe Foundation</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Crapo-1977" NAME="Crapo 1977" TYPE="JOURNAL_ARTICLE">
<AU>Crapo PA, Reaven G, Olefsky J Crapo PA, Reaven G, Olefsky J.</AU>
<TI>Postprandial plasma-glucose and -insulin responses to different complex carbohydrates</TI>
<SO>Diabetes</SO>
<YR>1977</YR>
<VL>26</VL>
<PG>1178-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fleiss-1981" NAME="Fleiss 1981" TYPE="BOOK">
<AU>Fleiss</AU>
<SO>Statistical Methods for Rates and Proportions</SO>
<YR>1981</YR>
<EN>2nd</EN>
<PB>Wiley, New York</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Franz-2004" NAME="Franz 2004" TYPE="JOURNAL_ARTICLE">
<AU>Bantle JP, Beebe C, Brunzell JD, Chiasson JL, Garg A, Franz MJ et al</AU>
<TI>Nutrition principles and recommendations in diabetes</TI>
<SO>Diabetes Care</SO>
<YR>2004</YR>
<VL>27</VL>
<NO>1 Suppl</NO>
<PG>S36-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goldstein--1995" NAME="Goldstein  1995" TYPE="JOURNAL_ARTICLE">
<AU>Goldstein DE, Little RR, Lorenz RA, Malone JI, Nathan DM, Peterson CM</AU>
<TI>Tests of glycemia in diabetes (Technical Review)</TI>
<SO>Diabetes Care</SO>
<YR>1995</YR>
<VL>18</VL>
<PG>896-909</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2002" NAME="Higgins 2002" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG</AU>
<TI>Quantifying heterogeneity in a meta-analysis</TI>
<SO>Statistics in medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>1539-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analysis</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2005" NAME="Higgins 2005" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]</TI>
<SO>In: The Cochrane Library, Issue 3, 2005. Chichester, UK: John Wiley &amp; Sons, Ltd</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Holman-1999" NAME="Holman 1999" TYPE="JOURNAL_ARTICLE">
<AU>Holman RR; Cull CA; Turner RC</AU>
<TI>A Randomized Double-Blind Trial of Acarbose in Type 2 Diabetes Shows Improved Glycemic Control Over 3 Years (U.K. Prospective Diabetes Study 44)</TI>
<SO>Diabetes Care</SO>
<YR>1999</YR>
<VL>22</VL>
<PG>960-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" NAME="Jadad 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ et al</AU>
<TI>Assessing the quality of reports of randomized clinical trials: is blinding necessary?</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jenkins-1981" NAME="Jenkins 1981" TYPE="JOURNAL_ARTICLE">
<AU>Jenkins DJ, Wolever TM, Taylor RH, Barker H, Fielden H, Baldwin JM et al</AU>
<TI>Glycemic index of foods: a physiological basis for carbohydrate exchange</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>1981</YR>
<VL>34</VL>
<NO>3</NO>
<PG>362-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-1999" NAME="Moher 1999" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF</AU>
<TI>Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses</TI>
<SO>Lancet</SO>
<YR>1999</YR>
<VL>354</VL>
<NO>9193</NO>
<PG>1896-900</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nield-2008" MODIFIED="2008-11-06 15:00:43 +0100" MODIFIED_BY="Bernd Richter" NAME="Nield 2008" TYPE="COCHRANE_REVIEW">
<AU>Nield L, Moore HJ, Hooper L, Cruickshank JK, Vyas A, Whittaker V, Summerbell CD</AU>
<TI>Dietary advice for treatment of type 2 diabetes mellitus in adults (Review)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>3</NO>
<PB>John Wiley &amp; Sons Ltd</PB>
<CY>London</CY>
<IDENTIFIERS MODIFIED="2008-11-06 15:00:43 +0100" MODIFIED_BY="Bernd Richter">
<IDENTIFIER MODIFIED="2008-11-06 15:00:43 +0100" MODIFIED_BY="Bernd Richter" TYPE="DOI" VALUE="10.1002/14651858.CD004097.pub4"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Salmeron-1997" NAME="Salmeron 1997" TYPE="JOURNAL_ARTICLE">
<AU>Salmeron J; Jenkins DJ; Ascerio A; Stampfer MJ; Rimm EB et al</AU>
<TI>Dietary fiber, glycemic load and risk of NIDDM in men</TI>
<SO>Diabetes Care</SO>
<YR>1997</YR>
<VL>20</VL>
<PG>545-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sheard-2004" NAME="Sheard 2004" TYPE="JOURNAL_ARTICLE">
<AU>Sheard NF.; Clark NG; Brand-Miller JC; Franz MJ; Pi-Sunyer FX; Mayer-Davis E; Kulkarni K; Geil P</AU>
<TI>Dietary Carbohydrate (Amount and Type) in the Prevention and Management of Diabetes: A statement by the American Diabetes Association</TI>
<SO>Diabetes Care</SO>
<YR>2004</YR>
<VL>27</VL>
<PG>2266-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Silink-2002" NAME="Silink 2002" TYPE="JOURNAL_ARTICLE">
<AU>Silink M</AU>
<TI>Childhood diabetes: a global perspective</TI>
<SO>Hormone Research</SO>
<YR>2002</YR>
<VL>57 Suppl 1</VL>
<PG>1-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stratton-2000" NAME="Stratton 2000" TYPE="JOURNAL_ARTICLE">
<AU>Stratton IM; Adler AI; Neil HA; Matthews DR; Manley SE.; Cull CA et al</AU>
<TI>Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study</TI>
<SO>British Medical Journal</SO>
<YR>2000</YR>
<VL>321</VL>
<PG>405-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tang-2000" NAME="Tang 2000" TYPE="JOURNAL_ARTICLE">
<AU>Tang JL, Liu JL</AU>
<TI>Misleading funnel plot for detection of bias in meta-analysis</TI>
<SO>Journal of clinical epidemiology</SO>
<YR>2000</YR>
<VL>53</VL>
<NO>5</NO>
<PG>477-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-UK-PDSG-1995" NAME="UK PDSG 1995" TYPE="JOURNAL_ARTICLE">
<AU>United Kingdom Prospective Diabetes Study Group</AU>
<TI>UKPDS 13: relative efficacy of randomly allocated diet, sulphonylurea, insulin or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years</TI>
<SO>British Medical Journal</SO>
<YR>1995</YR>
<VL>310</VL>
<PG>83-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-UKPDS-38-1998" NAME="UKPDS 38 1998" TYPE="JOURNAL_ARTICLE">
<AU>UK Prospective Diabetes Study Group</AU>
<TI>Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: (UKPDS 38)</TI>
<SO>BMJ</SO>
<YR>1998</YR>
<VL>317</VL>
<PG>703-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-UKPDS33-1998" NAME="UKPDS33 1998" TYPE="JOURNAL_ARTICLE">
<AU>UK Prospective Diabetes Study (UKPDS) Group</AU>
<TI>Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<PG>837-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Winocour-1988" NAME="Winocour 1988" TYPE="JOURNAL_ARTICLE">
<AU>Winocour P, Bhatnagar D, Kalsi P, Hillier V, Anderson D</AU>
<TI>Relative clinical usefulness of glycosylated serum albumin and fructosamine during short-term changes in glycemic control in IDDM</TI>
<SO>Diabetes Care</SO>
<YR>1988</YR>
<VL>12</VL>
<PG>665-72</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-11-12 11:40:52 +0100" MODIFIED_BY="Bernd Richter">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-11-12 11:40:52 +0100" MODIFIED_BY="Bernd Richter" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2008-11-06 16:42:21 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Brand-1991">
<CHAR_METHODS>
<P>Trial Design: RCT<BR/>Randomisation procedure: randomly assigned crossover design<BR/>Allocation concealment: not reported<BR/>Blinding of<BR/>outcome assessors: Not reported<BR/>Intention to treat analysis: Yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-06 16:42:21 +0100" MODIFIED_BY="Bernd Richter">
<P>Country: Australia<BR/>Setting: Community<BR/>Number: 16 in crossover design<BR/>Age: 62 ± 9 yr<BR/>Sex: 6 female, 10 male<BR/>Inclusion criteria: well-controlled NIDDM (defined by the National Diabetes Data Group), no history of ketosis or brittle diabetes, insidious onset of diabetes with minimal symptoms<BR/>Other characteristics: mean duration of diabetes 5 yr (range 1-22 yr), body mass 75.9 ± 14.1 kg. Body Mass Index 25 ± 5 kg/m2. All subjects in good healthy except for diabetes. Ten participants on sulfonylureas plus diet therapy, and six on diet therapy alone. Medication was not altered during study.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-06 15:18:48 +0100" MODIFIED_BY="Bernd Richter">
<P>Trial intervention: low glycaemic index diet<BR/>comparison intervention: high glycaemic index diet<BR/>Duration: 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Main outcome measures: %HbA1c, weight, fasting plasma glucose, urinary glucose, plama cholesterol, plasma triglycerides, low- and high- density lipoprotein cholesterol</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Source of funding: Sydney University Nutrition Research Foundation, CSL-Novo Pty Ltd, Apex-Australian Diabetes Foundation <BR/>Drop-outs: no</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-06 16:42:26 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Collier-1988">
<CHAR_METHODS MODIFIED="2008-11-06 16:06:31 +0100" MODIFIED_BY="Bernd Richter">
<P>Trial Design: RCT<BR/>Randomisation procedure: randomly assigned crossover design. Allocation concealment: not reported<BR/>Blinding of<BR/>outcome assessors: not reported<BR/>Intention to treat analysis: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-06 16:42:26 +0100" MODIFIED_BY="Bernd Richter">
<P>Country: Canada<BR/>Setting: community<BR/>Number: 7<BR/>Age: 12 ± 2 years<BR/>Sex: 6 male, 1 female<BR/>Inclusion criteria: Children with diabetes<BR/>Other characteristics: 102 ± 3% normal body weight, average insulin dose = 41.7 Units per day</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Trial intervention: low glycaemic index starchy diet<BR/>comparison intervention: high glycaemic index diet<BR/>Duration: 6 weeks per intervention with a 4 week washout period</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Main outcome measures: lipids, glucose, %HbA1c, glycosylated albumin<BR/>Other outcomes: C-peptide, insulin dose, growth</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Source of funding: Natural Sciences and Engineering Research Council of Canada and the Hospital for Sick Children Foundation<BR/>Drop-outs: no</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-06 16:42:41 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Fontvieille-1992">
<CHAR_METHODS>
<P>Trial Design: RCT<BR/>Randomisation procedure: not reported, crossover design<BR/>Allocation concealment: not reported<BR/>Blinding of outcome assessors: Unclear<BR/>Intention to treat analysis: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-06 16:42:33 +0100" MODIFIED_BY="Bernd Richter">
<P>Country: France<BR/>Setting: Community<BR/>Number: 18<BR/>Age: 47 ± 12 years<BR/>Sex: 12 male, 6 female<BR/>Inclusion criteria: well-controlled diabetes<BR/>Exclusion criteria: not stated<BR/>Other characteristics: type 1 diabetes n=12 (insulin controlled), type 2 diabetes n=6 (oral antidiabetic drugs), diabetes duration 12 ± 6 years, BMI 25 ± 3 kg /m2</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-06 16:42:41 +0100" MODIFIED_BY="Bernd Richter">
<P>Trial intervention: 5 weeks on low glycaemic index diet GI=38 ± 5 SD<BR/>comparison intervention: 5 weeks on high glycaemic index diet GI= 64 ± 2 SD<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Main outcome measures: fructosamine<BR/>Other outcomes: self-measured fasting blood glucose, postprandial blood glucose, daily blood glucose, body weight, HbA1c, insulin requirements, serum lipid levels</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Source of funding: BSN, General Biscuit France, Pierre and Marie Curie University, Paris<BR/>Drop-outs: no</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-06 16:45:58 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Frost-1994">
<CHAR_METHODS>
<P>Trial Design: RCT<BR/>Randomisation procedure: random number tables<BR/>Allocation concealment: not reported<BR/>Blinding of outcome assessors: not reported <BR/>Intention to treat analysis: no</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-06 16:45:58 +0100" MODIFIED_BY="Bernd Richter">
<P>Country: UK<BR/>Setting: Community<BR/>Number: 60<BR/>Age: intervention group 54 ± 2 years; comparison group 56 ± 3 years<BR/>Sex: low-GI diet group 16 males, 9 females, control group 20 males, 6 females<BR/>Inclusion criteria: newly diagnosed type 2 diabetes<BR/>Exclusion criteria: pregnant or lactating women, subjects aged more than 70 years, patients with other endocrine or lipid disorders, had received dietary advice previously, requiring oral hypoglycaemic or insulin therapy, patients where language barrier made instruction difficult<BR/>Other characteristics: BMI: low-GI group 30.1± 0.0 kg/m2, control group 29.1 ± 1.3 kg/m2</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-06 16:42:56 +0100" MODIFIED_BY="Bernd Richter">
<P>Trial intervention: 12 weeks low glycaemic index diet GI= 77 ± 1<BR/>comparison intervention: 12 weeks standard dietary advice GI= 82 ± 1<BR/>Duration: 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Main outcome measure: fructosamine<BR/>Other outcomes: fasting blood glucose, cholesterol, triglycerides, body weight</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Source of funding: British Diabetic Association<BR/>Drop-outs: 9, as they failed to complete the study as they did not attend the final appointment (5 in intervention group, 4 in comparison group)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-06 16:46:44 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Giacco-2000">
<CHAR_METHODS>
<P>Trial Design: RCT<BR/>Randomisation procedure: not stated, randomised with 2 parallel groups<BR/>Allocation concealment: not reported<BR/>Blinding: not reported<BR/>Intention to treat analysis: stated intention to treat, but all participants originally randomised not included (9 excluded)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-06 16:46:44 +0100" MODIFIED_BY="Bernd Richter">
<P>Country: Italy<BR/>Setting: community<BR/>Number: 63<BR/>Age: low-GI group 29 ± 11 years, high-GI group 26 ± 8 years<BR/>Sex: low-GI group 12 males,17 females, high-GI group 9 males, 16 females<BR/>Inclusion criteria: type 1 diabetic patients<BR/>Exclusion criteria: renal failure, liver disease or symptomatic cardiovascular disease<BR/>Other characteristics: C-peptide negative, BMI 23.9 ± 0.6 kg/m2, duration of diabetes 10.3 ± 6.3 years, treated with insulin, HbA1c levels between 7 and 10%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-06 15:18:54 +0100" MODIFIED_BY="Bernd Richter">
<P>Trial intervention: low glycaemic index diet (GI= 70%, 50g/day fibre,<BR/>comparison intervention: high gycemic index diet (GI=90%, 15 g/day fibre)<BR/>Duration: 24 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-06 15:18:55 +0100" MODIFIED_BY="Bernd Richter">
<P>Main outcome measure: % glycated haemoglobin, mean daily plasma glucose, lipids, hypoglycaemic events, body weight, insulin dose</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Source of funding: Italian National Research Council and Bayer Italy<BR/>Drop-outs: 9 drop outs, reasons not given</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-06 16:46:01 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Gilbertson-2001">
<CHAR_METHODS>
<P>Trial Design: RCT<BR/>Randomisation procedure: not reported, parallel study<BR/>Allocation concealment: not reported<BR/>Blinding of<BR/>outcome assessors: yes<BR/>Intention to treat analysis: yes, but not at 12 months Power calculation: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-06 16:46:01 +0100" MODIFIED_BY="Bernd Richter">
<P>Country: Australia<BR/>Setting: community<BR/>Number: 104 children, low-GI group n=55, CHOx group n=49<BR/>Age: children low-GI group 10.7 ± 1.6 years, CHOx group 10.2 ± 1.6 years<BR/>Sex: low-GI group 49% male, CHOx group 51% male<BR/>Inclusion criteria: children with type 1 diabetes</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-06 15:18:57 +0100" MODIFIED_BY="Bernd Richter">
<P>Trial intervention: low glycaemic index diet,<BR/>comparison intervention: measured carbohydrate exchange (CHOx)<BR/>Duration: 12 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Main outcome measures: % glycated haemoglobin, insulin dose, weight, height, dietary intake, incidence of hypo- and hyper-glycemia, quality of life</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Source of funding: Diabetes Australia Research Trust<BR/>Drop-outs: accounted for</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-06 16:46:44 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Jimenez_x002d_Cruz-2003">
<CHAR_METHODS>
<P>Trial Design: RCT<BR/>Randomisation procedure: not reported, randomly allocated crossover design<BR/>Allocation concealment: not reported<BR/>Blinding of outcome assessors: not reported<BR/>Intention to treat analysis: no</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-06 16:43:26 +0100" MODIFIED_BY="Bernd Richter">
<P>Country: Mexico<BR/>Setting: community<BR/>Number: 36 (14 completed study)<BR/>Age: 53 ± 9 years<BR/>Sex: of 14 who completed study 6 male, 8 female<BR/>Inclusion criteria: type 2 diabetes with BMI &gt;25 kg/m2<BR/>Other characteristics: mean diabetes duration 8 ± 7 years, BMI 30 ± 6 kg/m2, mean fasting glucose 9.5 mmol/L, mean A1c 8.4%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-06 15:18:59 +0100" MODIFIED_BY="Bernd Richter">
<P>Trial intervention: low glycaemic index diet<BR/>comparison intervention:<BR/>high glycaemic index diet<BR/>Duration: crossover design 2 x 6 week periods with 6 week washout period in between</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Main outcome measures: % glycated haemoglobin, weight, fasting serum glucose, BMI, body mass, serum lipids</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-11-06 16:46:44 +0100" MODIFIED_BY="Bernd Richter">
<P>Source of funding: Omnilife-Conacyt<BR/>Drop-outs: accounted for, 4 dropped out during the low-GI diet, 8 during the high-GI diet and 10 did not complete records</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-06 15:19:03 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Komindr-2001">
<CHAR_METHODS>
<P>Trial Design: RCT<BR/>Randomisation procedure: not reported<BR/>Allocation concealment: not reported<BR/>Blinding of outcome assessors: not reported<BR/>Intention to treat analysis: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-06 15:19:01 +0100" MODIFIED_BY="Bernd Richter">
<P>Country: Thailand<BR/>Setting: community<BR/>Number: 10<BR/>Age: 32-60 years<BR/>Sex: 10 female<BR/>Inclusion criteria: type 2 diabetes, absence of diabetic complications, co-operative, ability to consume the different test-diets, keep food records and be followed up for at least 4 months.<BR/>Other characteristics: non-insulin dependent treated with diet alone, or diet and oral hypoglycaemic agents, for 2 to 7 years, fasting plasma glucose levels 140 to 280 mg/dL</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-06 15:19:03 +0100" MODIFIED_BY="Bernd Richter">
<P>Trial intervention: low glycaemic index diet<BR/>comparison intervention:<BR/>high glycaemic index diet<BR/>Duration: 4 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Main outcome measures: HbA1c, plasma glucose and insulin, urinary glucose secretion, body weight</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Source of funding: Mahidol University, Sithinan Co Ltd<BR/>Drop-outs: no</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-06 16:46:45 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Luscombe-1999">
<CHAR_METHODS>
<P>Trial Design: RCT<BR/>Randomisation procedure: not stated, randomly assigned crossover design<BR/>Allocation concealment: not reported<BR/>Blinding: not reported<BR/>Intention to treat analysis: no</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-06 16:43:32 +0100" MODIFIED_BY="Bernd Richter">
<P>Country: Australia<BR/>Setting: community<BR/>Number: 28 (7 dropouts), 21 analysed<BR/>Age: 57.4 ± 2.9 years<BR/>Sex: 14 males, 7 females<BR/>Body mass: 87 ± 3 kg<BR/>Inclusion criteria: NIDDM but no history of renal disease, retinopathy or vascular problems<BR/>Other characteristics: 16 subjects treated with oral hypoglycaemic agents (sulphonylureas and metformin) and 5 by diet alone. Drug dosage was not altered during study.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-06 16:46:45 +0100" MODIFIED_BY="Bernd Richter">
<P>Trial intervention: low-GI diet (GI=63 GI units using glucose =100)<BR/>comparison intervention: high-GI diet (GI=43 GI units)<BR/>Duration of each intervention: 4 weeks with no washout period between interventions<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Main outcome measures: fructosamine, glycated plasma protein (%)<BR/>Other outcomes: plasma insulin, urinary glucose, urinary C-peptide, plasma lipids, plasma glucose, body weight</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Source of funding: CSIRO Human Nutrition <BR/>Drop-outs: 7 (due to work commitments and illness unrelated to diabetes)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-12 11:40:52 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Rizkalla-2004">
<CHAR_METHODS>
<P>Trial Design: RCT<BR/>Randomisation procedure: not stated, randomly allocated crossover design<BR/>Allocation concealment: not reported<BR/>Blinding: not reported<BR/>Intention to treat analysis: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-12 11:40:52 +0100" MODIFIED_BY="Bernd Richter">
<P>Country: France<BR/>Setting: community<BR/>Number: 12<BR/>Age: 54 ± 2 years<BR/>Sex: 12 males<BR/>Body mass: 93 ± 3 kg,<BR/>Inclusion criteria: type 2 diabetes Other characteristics: BMI 31 ± 1 kg/m2, fasting glycaemia 8.7 ± 0.7 mmol/L, 11 men on antidiabetic agents and 1 on dietary regime alone.<BR/>Exclusion criteria: abnormal renal, hepatic and thyroid functions</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-06 16:46:45 +0100" MODIFIED_BY="Bernd Richter">
<P>Trial intervention: low-GI diet<BR/>comparison intervention: high-GI diet (GI= GI units)<BR/>Duration of each intervention: 4 weeks with 4 week washout period between interventions</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Main outcome measures: % glycated haemoglobin<BR/>Other outcomes: plasma glucose, plasma insulin, plasma lipids, body weight</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Source of funding: INSERM<BR/>Drop-outs: no</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-06 16:43:50 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Wolever-1992">
<CHAR_METHODS>
<P>Trial Design: RCT<BR/>Randomisation procedure: not reported, crossover design<BR/>Allocation concealment: not reported<BR/>Blinding of outcome assessors: not reported<BR/>Intention to treat analysis: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-06 16:43:50 +0100" MODIFIED_BY="Bernd Richter">
<P>Country: Canada<BR/>Setting: community<BR/>Number: 6 in crossover study<BR/>Age: 63 ± 4 years<BR/>Sex: 3 male, 3 female<BR/>Inclusion criteria: NIDDM plus obese/overweight<BR/>Other characteristics: BMI 32.1 ± 2.4kg/m2</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-06 15:19:06 +0100" MODIFIED_BY="Bernd Richter">
<P>Trial intervention: low glycaemic index diet GI= 58,<BR/>comparison intervention: high glycaemic index diet GI=86<BR/>Duration of study: 6 weeks. 4 to 6 week washout period in between diets.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Main outcome measures: fructosamine, body weight, lipids</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Source of funding: Canadian Diabetes Association, Bristol Myers Company, NY<BR/>Drop-outs: 2 subjects were sampled one week early for the final analysis for both diets.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>GI = glycaemic index<BR/>RCT= randomised controlled trial<BR/>BMI = Body Mass Index<BR/>NIDDM = non-insulin dependent diabetes mellitus<BR/>CHOx = Measured carbohydrate exchange<BR/>%HbA1c = percentage glycated haemoglobin</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2008-11-06 16:43:54 +0100" MODIFIED_BY="Bernd Richter" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2008-11-06 16:21:34 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Heilbronn-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-06 16:21:34 +0100" MODIFIED_BY="Bernd Richter">
<P>Participants were of unknown diabetic status at the start of the intervention (diabetic or improved diabetic), although all had previously been diagnosed as having type 2 diabetes in the last ten years</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jarvi-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duration of intervention less than 4 weeks (24 days)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jenkins-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duration of intervention less than 4 weeks (2 weeks)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lafrance-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duration of intervention less than 4 weeks (12 days)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ma-2008">
<CHAR_REASON_FOR_EXCLUSION>
<P>Co-intervention of alteration of the medications when diagnosed as necessary according to %HbA1c levels</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wolever-1992-b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duration of intervention less than 4 weeks (2 weeks)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-06 16:43:54 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Wolever-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-06 16:43:54 +0100" MODIFIED_BY="Bernd Richter">
<P>Participants commenced the study with already optimised HbA1c levels (6.2 ± 1% HbA1c) and hence this study was excluded, since the effect of diet on HbA1c was our primary outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Brand-1991">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Collier-1988">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Fontvieille-1992">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Frost-1994">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Giacco-2000">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Gilbertson-2001">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Jimenez_x002d_Cruz-2003">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Komindr-2001">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Luscombe-1999">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Rizkalla-2004">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Wolever-1992">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2008-10-08 15:04:09 +0200" MODIFIED_BY="[Empty name]"/>
<ADDITIONAL_TABLES MODIFIED="2008-11-06 14:30:44 +0100" MODIFIED_BY="Bernd Richter"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-11-12 10:35:49 +0100" MODIFIED_BY="Bernd Richter">
<COMPARISON ID="CMP-001" MODIFIED="2008-11-12 10:35:49 +0100" MODIFIED_BY="Bernd Richter" NO="1">
<NAME>Low glycaemic index or low glycaemic load diet versus other diet</NAME>
<CONT_OUTCOME CHI2="1.3138638749155915" CI_END="-0.19652280729492622" CI_START="-0.8061241767086534" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.5013234920017898" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.01" MODIFIED="2008-11-12 10:35:27 +0100" MODIFIED_BY="Bernd Richter" NO="1" P_CHI2="0.9334986602246524" P_Q="1.0" P_Z="0.0012656036262269136" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="132" TOTAL_2="115" UNITS="" WEIGHT="100.0" Z="3.223667262664899">
<NAME>Glycated haemoglobin (%HbA1c)</NAME>
<GROUP_LABEL_1>Favours low glycemic</GROUP_LABEL_1>
<GROUP_LABEL_2>Favours control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours low glycemic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.12313123725118902" CI_START="-1.9231312372511897" EFFECT_SIZE="-0.9000000000000004" ESTIMABLE="YES" MEAN_1="7.0" MEAN_2="7.9" MODIFIED="2008-11-12 10:32:14 +0100" MODIFIED_BY="Bernd Richter" ORDER="23627" SD_1="0.6" SD_2="2.0" SE="0.5220153254455275" STUDY_ID="STD-Brand-1991" TOTAL_1="16" TOTAL_2="16" WEIGHT="8.875016883021171"/>
<CONT_DATA CI_END="0.32621618754567416" CI_START="-0.926216187545672" EFFECT_SIZE="-0.29999999999999893" ESTIMABLE="YES" MEAN_1="8.8" MEAN_2="9.1" MODIFIED="2008-11-12 10:34:13 +0100" MODIFIED_BY="Bernd Richter" ORDER="23628" SD_1="1.0" SD_2="1.3" SE="0.31950392582985526" STUDY_ID="STD-Giacco-2000" TOTAL_1="29" TOTAL_2="25" WEIGHT="23.69099477032658"/>
<CONT_DATA CI_END="-0.07706489474798683" CI_START="-1.1229351052520125" EFFECT_SIZE="-0.5999999999999996" ESTIMABLE="YES" MEAN_1="8.0" MEAN_2="8.6" MODIFIED="2008-11-12 10:34:13 +0100" MODIFIED_BY="Bernd Richter" ORDER="23629" SD_1="1.0" SD_2="1.4" SE="0.2668085277978872" STUDY_ID="STD-Gilbertson-2001" TOTAL_1="51" TOTAL_2="38" WEIGHT="33.973186365670465"/>
<CONT_DATA CI_END="0.16671707908037214" CI_START="-1.1667170790803723" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="8.1" MEAN_2="8.6" MODIFIED="2008-11-12 10:32:14 +0100" MODIFIED_BY="Bernd Richter" ORDER="23630" SD_1="0.9" SD_2="0.9" SE="0.3401680257083045" STUDY_ID="STD-Jimenez_x002d_Cruz-2003" TOTAL_1="14" TOTAL_2="14" WEIGHT="20.900116918966525"/>
<CONT_DATA CI_END="1.3980935773482497" CI_START="-1.7580935773482491" EFFECT_SIZE="-0.17999999999999972" ESTIMABLE="YES" MEAN_1="10.97" MEAN_2="11.15" MODIFIED="2008-11-12 10:32:15 +0100" MODIFIED_BY="Bernd Richter" ORDER="23631" SD_1="1.55" SD_2="2.02" SE="0.805164579449444" STUDY_ID="STD-Komindr-2001" TOTAL_1="10" TOTAL_2="10" WEIGHT="3.730494224225685"/>
<CONT_DATA CI_END="0.6257248883957347" CI_START="-1.4257248883957354" EFFECT_SIZE="-0.40000000000000036" ESTIMABLE="YES" MEAN_1="7.17" MEAN_2="7.57" MODIFIED="2008-11-12 10:32:16 +0100" MODIFIED_BY="Bernd Richter" ORDER="23632" SD_1="1.35" SD_2="1.21" SE="0.5233386411620428" STUDY_ID="STD-Rizkalla-2004" TOTAL_1="12" TOTAL_2="12" WEIGHT="8.830190837789578"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.605870475050195" CI_END="0.0021693552572983887" CI_START="-0.4694555799762632" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.2336431123594824" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2008-11-12 10:35:49 +0100" MODIFIED_BY="Bernd Richter" NO="2" P_CHI2="0.4564613525934015" P_Q="1.0" P_Z="0.052145174439281745" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="70" TOTAL_2="71" UNITS="" WEIGHT="100.0" Z="1.941933308651928">
<NAME>Fructosamine (mMol/L)</NAME>
<GROUP_LABEL_1>Favours low glycemic</GROUP_LABEL_1>
<GROUP_LABEL_2>Favours control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours low glycemic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.009846614476780036" CI_START="-0.9498466144767795" EFFECT_SIZE="-0.46999999999999975" ESTIMABLE="YES" MEAN_1="3.41" MEAN_2="3.88" MODIFIED="2008-11-12 10:34:20 +0100" MODIFIED_BY="Bernd Richter" ORDER="23633" SD_1="0.42" SD_2="0.95" SE="0.2448241999657895" STUDY_ID="STD-Fontvieille-1992" TOTAL_1="18" TOTAL_2="18" WEIGHT="24.150640644365556"/>
<CONT_DATA CI_END="0.14900525408078602" CI_START="-0.9490052540807858" EFFECT_SIZE="-0.3999999999999999" ESTIMABLE="YES" MEAN_1="3.2" MEAN_2="3.6" MODIFIED="2008-11-12 10:07:32 +0100" MODIFIED_BY="Bernd Richter" ORDER="23634" SD_1="1.0" SD_2="1.0" SE="0.28010986855435577" STUDY_ID="STD-Frost-1994" TOTAL_1="25" TOTAL_2="26" WEIGHT="18.449326823838668"/>
<CONT_DATA CI_END="0.2579102897145004" CI_START="-0.37791028971449964" EFFECT_SIZE="-0.05999999999999961" ESTIMABLE="YES" MEAN_1="3.22" MEAN_2="3.28" MODIFIED="2008-11-12 10:34:19 +0100" MODIFIED_BY="Bernd Richter" ORDER="23635" SD_1="0.5" SD_2="0.55" SE="0.1622021079071533" STUDY_ID="STD-Luscombe-1999" TOTAL_1="21" TOTAL_2="21" WEIGHT="55.02047762848929"/>
<CONT_DATA CI_END="0.9686881465019579" CI_START="-2.088688146501959" EFFECT_SIZE="-0.5600000000000005" ESTIMABLE="YES" MEAN_1="4.56" MEAN_2="5.12" MODIFIED="2008-11-12 10:34:19 +0100" MODIFIED_BY="Bernd Richter" ORDER="23636" SD_1="1.3" SD_2="1.4" SE="0.779957263786506" STUDY_ID="STD-Wolever-1992" TOTAL_1="6" TOTAL_2="6" WEIGHT="2.379554903306484"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2008-11-06 12:59:16 +0100" MODIFIED_BY="Bernd Richter">
<FIGURE FILENAME="thomas qourom.jpg" FILE_TYPE="JPG" ID="FIG-01" MODIFIED="2008-11-06 12:59:16 +0100" MODIFIED_BY="Bernd Richter" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Adapted QUOROM (quality of reporting of meta-analyses) flow-chart of study selection</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2009-05-12 16:47:52 +0200" MODIFIED_BY="Bernd Richter">
<FEEDBACK_ITEM ID="FBK-01" MODIFIED="2009-05-12 16:47:52 +0200" MODIFIED_BY="Bernd Richter" NO="1">
<TITLE MODIFIED="2009-05-12 16:35:01 +0200" MODIFIED_BY="Bernd Richter">Description of the intervention</TITLE>
<DATE_SUBMITTED>
<DATE DAY="20" MONTH="3" YEAR="2009"/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2009-05-12 16:36:00 +0200" MODIFIED_BY="Bernd Richter">
<P>The intervention isn't clearly described in a way that would allow it to be reproduced (or at least I couldn't find this - it isn't in the "Description of the intervention"). As it doesn't define what constitutes low GI or low glycaemic load, a reader with diabetes might not know what the implications of this review's findings are for improving his or her diet.</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2009-05-12 16:47:52 +0200" MODIFIED_BY="Bernd Richter">
<P>As the glycaemic index (GI) represents the degree that a carbohydrate can raise the blood glucose, it is necessary to test a food in people to determine its GI, rather than predict the GI through its structure. The  GI of a food can be affected by several factors such as the cooking method used for preparation, the form of the food, the type of starch it contains, how much fibre it contains and also how much and what type of sugar is present in the food.  Processing increases the gelatinised starch content and so can raise the GI of the food. Grains and legumes that have fibrous husks, as well as foods containing soluble fibre, such as oatmeal and apples tend to have a lower GI.<BR/>The low GI diet is a diet generally high in carbohydrate foods, but with legumes, whole grains (eg oats, barley, rye), and low GI versions of bread, rice, pasta, fruit and vegetables forming the basis. A low GI diet can be achieved by substituting the high GI foods in the diet with lower GI alternatives. Hence, consuming semolina, muesli or porridge instead of processed cereals; basmati rice, instead of short grain rice; sweet potato instead of white potato; whole grain, rye or sourdough bread instead of white bread can significantly lower the GI of the diet. Pasta is also a low GI option. If the lower GI alternative food is eaten for these carbohydrate rich foods, then a low GI diet can include whatever types of vegetables and meat that are required to provide a balanced healthy diet, as these contain, by comparison, little carbohydrate.<BR/>These changes from higher to lower GI foods can be gradually incorporated into the eating pattern, so that they become part of the normal diet and the GI of the overall diet significantly lowers.</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2009-05-12 16:40:23 +0200" MODIFIED_BY="Bernd Richter">
<P>Comments made by Amanda, occupation doctor ( <A HREF="mailto:ajburls@yahoo.co.uk">ajburls@yahoo.co.uk</A>).</P>
<P>Diana Thomas replied to the comments on behalf of the review authors for the review.</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES MODIFIED="2008-11-06 16:05:50 +0100" MODIFIED_BY="Bernd Richter">
<APPENDIX ID="APP-01" MODIFIED="2008-11-06 14:25:35 +0100" MODIFIED_BY="Bernd Richter" NO="1">
<TITLE MODIFIED="2008-10-08 14:09:00 +0200" MODIFIED_BY="[Empty name]">Search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-11-06 14:25:35 +0100" MODIFIED_BY="Bernd Richter">
<TABLE COLS="1" ROWS="2">
<TR>
<TH>
<P>Search terms</P>
</TH>
</TR>
<TR>
<TD>
<P>Unless otherwise stated, search terms are free text terms; MeSH = Medical subject heading (Medline medical index term); exp = exploded MeSH; the dollar sign ($) stands for any character(s); the question mark (?) = to substitute for one or no characters; tw = text word; pt = publication type; sh = MeSH; adj = adjacent.</P>
<P>
<B>MEDLINE:</B>
</P>
<P>A) Diabetes mellitus, general<BR/>
<BR/>1 exp diabetes mellitus/<BR/>2 diabet$.tw.<BR/>3 IDDM.tw.<BR/>4 NIDDM.tw.<BR/>5 MODY.tw.<BR/>6 insulin$ secret$ dysfunc$.tw.<BR/>7 impaired glucose toleran$.tw.<BR/>8 exp glucose intolerance/<BR/>9 glucose intoleran$.tw.<BR/>10 exp insulin resistance/<BR/>11 insulin$ resist$.tw.<BR/>12 (non insulin$ depend$ or noninsulin$ depend$ or<BR/>non insulin?depend$ or noninsulin?depend$).tw.<BR/>13 (insulin? depend$ or insulin?depend$).tw<BR/>14 metabolic$ syndrom$.tw.<BR/>15 (pluri metabolic$ syndrom$ or plurimetabolic$ syndrom$).tw.<BR/>16 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15<BR/>17 exp diabetes insipidus/<BR/>18 diabet$ insipidus.tw.<BR/>19 17 or 18<BR/>20 16 not 19<BR/>
<BR/>B) Controlled trials*<BR/>
<BR/>21 randomized-controlled trial.pt.<BR/>22 controlled-clinical trial.pt.<BR/>23 randomized-controlled-trials.sh.<BR/>24 random allocation.sh.<BR/>25 double-blind method.sh.<BR/>26 single-blind method.sh.<BR/>27 21 or 22 or 23 or 24 or 25 or 26<BR/>28 animal.sh.<BR/>29 human.sh.<BR/>30 28 not 29<BR/>31 27 not 30<BR/>
<BR/>C) Glycaemic index or glycaemic load<BR/>
<BR/>32 (diet adj5 glyc?emic$).tw.<BR/>33 Glycemic Index/ or glyc?emic index.tw.<BR/>34 (all bran or wholegrain or pasta or oat$ or apple$ or appricot$ or bean$ or lentil$ or wheat bran or barley porridge or raw oats or basmati rice).ti, ab.<BR/>35 (gi adj10 (diet or food or carbohydrate$)).tw.<BR/>36 (food adj5 glyc?emic$).tw.<BR/>37 (carbohydrate$ adj5 (blood glucose or blood sugar) adj5 (low or less$ or high$)).tw.<BR/>38 (puls$ adj10 (diet or food)).tw.<BR/>39 lentil$.tw.<BR/>40 or/32-39<BR/>41 dietary carbohydrates/<BR/>42 blood glucose.sh,rn,rw.<BR/>43 41 and 42<BR/>44 40 or 43<BR/>
<BR/>D) Systematic reviews, meta-analyses, health-technology assessment reports<BR/>45 exp meta-analysis/<BR/>46 exp Review Literature/<BR/>47 meta-analysis.pt.<BR/>48 systematic review$.tw.<BR/>49 search$.tw.<BR/>50 medline.tw.<BR/>51 cochrane database of systematic reviews.jn.<BR/>52 45 or 46 or 47 or 48 or 49 or 50 or 51<BR/>53 letter.pt.<BR/>54 comment.pt.<BR/>55 editorial.pt.<BR/>56 historical-article.pt.<BR/>57 53 or 54 or 55 or 56<BR/>58 52 not 57<BR/>59 exp Technology Assessment, Biomedical/<BR/>60 HTA.tw.<BR/>61 (health technology adj6 assessment$).tw.<BR/>62 (biomedical adj6 technology assessment$).tw.<BR/>63 60 or 61 or 62<BR/>64 58 or 63<BR/>
<BR/>65 31 or 64<BR/>66 20 and 44<BR/>67 65 and 66<BR/>
<BR/>* Robinson KA, Dickersin K. Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed. International Journal of Epidemiology 2002;31:150-3.</P>
</TD>
</TR>
</TABLE>
<P/>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2008-11-06 16:05:50 +0100" MODIFIED_BY="Bernd Richter" NO="2">
<TITLE MODIFIED="2008-11-06 14:21:09 +0100" MODIFIED_BY="Bernd Richter">Risk of bias</TITLE>
<APPENDIX_BODY MODIFIED="2008-11-06 16:05:50 +0100" MODIFIED_BY="Bernd Richter">
<TABLE COLS="7" ROWS="12">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>At baseline</P>
</TH>
<TH>
<P>Randomisation</P>
</TH>
<TH>
<P>Allocation concealed</P>
</TH>
<TH>
<P>Intention-to -treat</P>
</TH>
<TH>
<P>Assessor blinding</P>
</TH>
<TH>
<P>Losses accounted for</P>
</TH>
</TR>
<TR>
<TD>
<P>Brand 1991</P>
</TD>
<TD>
<P>similar</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>not reported</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>not reported</P>
</TD>
<TD>
<P>no losses</P>
</TD>
</TR>
<TR>
<TD>
<P>Collier 1988</P>
</TD>
<TD>
<P>similar</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>not reported</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>not reported</P>
</TD>
<TD>
<P>no losses</P>
</TD>
</TR>
<TR>
<TD>
<P>Fontvieille 1992</P>
</TD>
<TD>
<P>similar</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>not reported</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>not reported</P>
</TD>
<TD>
<P>no losses</P>
</TD>
</TR>
<TR>
<TD>
<P>Frost 1994</P>
</TD>
<TD>
<P>similar</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>not reported</P>
</TD>
<TD>
<P>no</P>
</TD>
<TD>
<P>not reported</P>
</TD>
<TD>
<P>failed to complete study</P>
</TD>
</TR>
<TR>
<TD>
<P>Giacco 2000</P>
</TD>
<TD>
<P>similar</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>not reported</P>
</TD>
<TD>
<P>no</P>
</TD>
<TD>
<P>not reported</P>
</TD>
<TD>
<P>reasons not given</P>
</TD>
</TR>
<TR>
<TD>
<P>Gilbertson 2001</P>
</TD>
<TD>
<P>similar</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>not reported</P>
</TD>
<TD>
<P>yes, but not at 12 months</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>yes</P>
</TD>
</TR>
<TR>
<TD>
<P>Jimenez-Cruz 2003</P>
</TD>
<TD>
<P>similar</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>not reported</P>
</TD>
<TD>
<P>no</P>
</TD>
<TD>
<P>not reported</P>
</TD>
<TD>
<P>yes</P>
</TD>
</TR>
<TR>
<TD>
<P>Komindr 2001</P>
</TD>
<TD>
<P>similar</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>not reported</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>not reported</P>
</TD>
<TD>
<P>no losses</P>
</TD>
</TR>
<TR>
<TD>
<P>Luscombe 1999</P>
</TD>
<TD>
<P>similar</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>not reported</P>
</TD>
<TD>
<P>no</P>
</TD>
<TD>
<P>not reported</P>
</TD>
<TD>
<P>yes</P>
</TD>
</TR>
<TR>
<TD>
<P>Rizkalla 2004</P>
</TD>
<TD>
<P>similar</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>not reported</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>not reported</P>
</TD>
<TD>
<P>no losses</P>
</TD>
</TR>
<TR>
<TD>
<P>Wolever 1992</P>
</TD>
<TD>
<P>similar</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>not reported</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>not reported</P>
</TD>
<TD>
<P>2 participants sampled 1 week early for final analysis for both diets</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2008-11-06 14:29:38 +0100" MODIFIED_BY="Bernd Richter" NO="3">
<TITLE MODIFIED="2008-11-06 14:22:22 +0100" MODIFIED_BY="Bernd Richter">Original study data</TITLE>
<APPENDIX_BODY MODIFIED="2008-11-06 14:29:38 +0100" MODIFIED_BY="Bernd Richter">
<P>
<BR/>
</P>
<TABLE COLS="1" ROWS="1">
<TR>
<TD>
<P>
<B>Glycaemic index or low glycaemic load diet versus other diet</B>
<BR/>
<I>Glycated haemoglobin (%HbA1c)</I>
<BR/>Study ID: Low glycaemic N Low glycaemic Mean Low glycaemic SD Control N Control Mean Control SD<BR/>Brand 1991: 16 7.00 0.60 16 7.90 2.00<BR/>Giacco 2000: 29 8.80 1.00 25 9.10 1.30<BR/>Gilbertson 2001: 51 8.00 1.00 38 8.60 1.40<BR/>Komindr 2001: 10 10.97 1.55 10 11.15 2.02<BR/>Jiminez-Cruz 2003: 14 8.10 0.90 14 8.60 0.90<BR/>Rizkalla 2004: 12 7.17 1.35 12 7.57 1.21<BR/>
<BR/>
<I>Fructosamine</I>
<BR/>Study ID: Treatment N Treatment Mean Treatment SD Control N Control Mean Control SD<BR/>Fontvieille 1992: 18 3.41 0.95 18 3.88 0.42<BR/>Frost 1994: 25 3.20 1.00 26 3.60 1.00<BR/>Luscombe 1999: 21 3.22 5.04 21 3.28 5.50<BR/>Wolever 1992: 6 4.56 1.30 6 5.12 1.40<BR/>
<BR/>
<I>Episodes of hypoglycemia</I>
<BR/>Study ID: Treatment N Treatment Mean Treatment SD Control N Control Mean Control SD<BR/>Giacco 2000: 29 0.70 0.70 25 1.50 1.20<BR/>Gilbertson 2001: 51 6.90 6.80 38 5.80 5.50</P>
</TD>
</TR>
</TABLE>
<P/>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2008-11-06 14:31:32 +0100" MODIFIED_BY="Bernd Richter" NO="4">
<TITLE MODIFIED="2008-11-06 14:22:41 +0100" MODIFIED_BY="Bernd Richter">Baseline percentage glycated haemoglobin values reported in studies</TITLE>
<APPENDIX_BODY MODIFIED="2008-11-06 14:31:32 +0100" MODIFIED_BY="Bernd Richter">
<TABLE COLS="5" ROWS="9">
<TR>
<TD>
<P>Significantly different from endpoint</P>
</TD>
<TD>
<P>1.4 SEM</P>
</TD>
<TD>
<P>8.3 (baseline not significantly different from endpoint)</P>
</TD>
<TD>
<P>1.5 SEM</P>
</TD>
<TD>
<P>Giacco 2000</P>
</TD>
</TR>
<TR>
<TD>
<P>8.8</P>
</TD>
<TD>
<P>1.4 SD</P>
</TD>
<TD>
<P>8.8</P>
</TD>
<TD>
<P>1.4 SD</P>
</TD>
<TD>
<P>Gilbertson 2001</P>
</TD>
</TR>
<TR>
<TD>
<P>8.3</P>
</TD>
<TD>
<P>1.3 SD</P>
</TD>
<TD>
<P>8.6 (carbohydrate exchange)</P>
</TD>
<TD>
<P>1.4 SD</P>
</TD>
<TD>
<P>Jimenez-Cruz 2003</P>
</TD>
</TR>
<TR>
<TD>
<P>8.5</P>
</TD>
<TD>
<P>0.3 SEM</P>
</TD>
<TD>
<P>8.6</P>
</TD>
<TD>
<P>0.3 SEM</P>
</TD>
<TD>
<P>Komindr 2001</P>
</TD>
</TR>
<TR>
<TD>
<P>13.8</P>
</TD>
<TD>
<P>1.1 SEM</P>
</TD>
<TD>
<P>13.8</P>
</TD>
<TD>
<P>1.1 SEM</P>
</TD>
<TD>
<P>Rizkalla 2004</P>
</TD>
</TR>
<TR>
<TD>
<P>7.6</P>
</TD>
<TD>
<P>0.4 SE</P>
</TD>
<TD>
<P>7.5</P>
</TD>
<TD>
<P>0.4 SE</P>
</TD>
<TD>
<P>Studies with HbA1c levels already less than 7.0% at baseline (excluded)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Heilbronn 2002 (mixed diabetic/ improved diabetic subjects. Diabetic status unknown at baseline)</P>
</TD>
</TR>
<TR>
<TD>
<P>6.6</P>
</TD>
<TD>
<P>0.3 SEM</P>
</TD>
<TD>
<P>6.3</P>
</TD>
<TD>
<P>0.3 SEM</P>
</TD>
<TD>
<P>Wolever 2008 (Participants already had optimal mean HbA1c at baseline)</P>
</TD>
</TR>
<TR>
<TD>
<P>6.2</P>
</TD>
<TD>
<P>0.8 SEM</P>
</TD>
<TD>
<P>6.2</P>
</TD>
<TD>
<P>1.0 SEM</P>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>